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 Anxiety is linked to dysregulation of neuronal activity in several brain regions including 
the infralimbic (IL) area of the medial prefrontal cortex (mPFC) and the basolateral nucleus of the 
amygdala (BLA). Disruptions to the balance of excitatory and inhibitory signaling in these regions 
are implicated in anxiety-like behaviors in animals and anxiety disorders in humans. The neuronal 
circuitry between excitatory neurons, known as pyramidal cells (P-cells), and inhibitory neurons, 
known as interneurons (INs), is a primary target for anxiety modulation at the cellular level. INs, 
particularly the subtype that contain the neuropeptide cholecystokinin (CCK+INs), form inhibitory 
synapses around P-cells. Through GABAergic neurotransmitter release, CCK+INs regulate P-cell 
activity and subsequent anxiety-related neuronal output. Two protein complexes, the N-type 
calcium channel (CaV2.2) and the type-1 cannabinoid receptor (CB1), are expressed in the 
presynaptic terminal of CCK+INs. CaV2.2 and CB1 have been shown to regulate neurotransmitter 
release from CCK+INs in the hippocampus, but it is not known if this role is conserved in the 
anxiety-related neuronal circuits of the BLA and IL. CaV2.2 has also been shown to regulate the 
intrinsic firing properties of P-cells in the hippocampus and deep cerebellar nuclei, but this role 
has not been assessed in the IL. To investigate these neuronal circuits, I used a combination of 
transgenic mouse models, confocal microscopy, patch-clamp electrophysiology, optogenetics, and 
 ix 
pharmacology. In the first chapter of my thesis, I investigated the role of CaV2.2 in CCK+IN/P-
cell synapses in the BLA. In the second chapter of my thesis, I investigated the role of CB1 in 
regulating GABA release from CCK+INs in the BLA. In the third chapter of my thesis, I assessed 
the regulation of GABA release and intrinsic firing by CaV2.2 in the IL. I present electrophysiology 
data which demonstrate GABA release from CCK+INs is partially CaV2.2-dependent in the BLA. 
I obtained preliminary electrophysiology recordings which suggest CB1 receptors modulate GABA 
release in CCK+IN/P-cell synapses in the BLA. I found that neurotransmitter release from 
GABAergic INs is partially CaV2.2-dependent in the IL. However, I found that GABA release 
from CCK+INs is not CaV2.2-dependent in this region. Lastly, I observed that CaV2.2 plays a 
minimal role in the intrinsic firing properties of P-cells in the IL. My findings suggest that CaV2.2 
differentially regulates GABA release and intrinsic firing properties across brain regions, 





Fear and anxiety are normal experiences in day-to-day life. Fear often results from an 
apparent external danger, while anxiety is a widespread response to an unknown or non-specific 
threat. Both trigger appropriate and adaptive responses to risks, be they physical, mental, or 
societal (Steimer, 2002). When fear and anxiety become pathological, they can manifest as an 
anxiety disorder. Anxiety disorders include panic disorder, generalized anxiety disorder, 
agoraphobia, specific phobias, social anxiety disorder, post-traumatic stress disorder, obsessive-
compulsive disorder, and separation anxiety disorder. In these conditions, an individual’s ability 
to cope with various stressors is compromised, meaning non-threatening stimuli can cause severe 
distress. Anxiety disorders alter numerous physiological processes, facilitating poor physical 
health outcomes over time (Kroenke, Spitzer, Williams, Monahan, & Löwe, 2007). The National 
Institute of Mental Health reports a 19.1% past-year prevalence of anxiety disorders in U.S. adults 
(Harvard Medical School National Comorbidity Survey, 2017). Current medications used to treat 
anxiety disorders (benzodiazepines, selective serotonin reuptake inhibitors) cause several adverse 
effects (impaired cognition, addiction), thus many patients withdraw from treatment (Baldwin, 
Woods, Lawson, & Taylor, 2011). A greater understanding of the neurobiology behind anxiety 
disorders is required to produce more effective treatments. 
Anxiety is a highly integrated emotional component of cognitive processing facilitated by 
the thalamus, locus coeruleus, hypothalamus, hippocampus, amygdalar nuclei, and the prefrontal, 
sensory, entorhinal, and association cortices (Steimer, 2002). Classically, these brain areas are 
defined as components of the limbic system or ‘emotional brain.’ In animal models, their 
connections are implicated in emotional learning and conduct, including fear-conditioning and 
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anxiety-like behaviors (Steimer, 2002). Of particular importance for their role in modulating 
anxiety are the medial prefrontal cortex (mPFC) and the basolateral amygdala (BLA). The mPFC 
processes the cognitive components of anxiety (i.e. rumination) and mediates sympathetic nervous 
system responses (fight-or-flight). The behavioral responses related to anxiety (i.e. avoidance) are 
modulated by the BLA (Johansen, Cain, Ostroff, & Ledoux, 2011). While each area has 
independent roles in anxiety, their interconnections are involved in fear expression and the 
extinction of conditioned fear (Ferreira, Yousuf, Dalton, & Sheets, 2015; Milad & Quirk, 2002; 
Phelps, Delgado, Nearing, & Ledoux, 2004). Research targeting the neural circuits involved in this 
disruption may provide insight as to how anxiety is regulated at the cellular level.  
The balance between excitatory and inhibitory activity in the mPFC and BLA is disrupted 
in anxiety disorders (Ehrlich et al., 2009). Pyramidal neurons (P-cells) are the primary excitatory 
cell type in the mPFC and BLA. P-cells receive excitatory inputs through projections from other 
brain areas and inhibitory inputs from local interneurons (INs) (Freund, 2003). Multiple types of 
INs exist, and the cholecystokinin-containing subtype (CCK+INs) are strongly linked to anxiety-
related behaviors (Truitt, Johnson, Dietrich, Fitz, & Shekhar, 2009). The inhibitory 
neurotransmitter gamma-aminobutyric acid (GABA) is released from CCK+INs onto P-cells, 
decreasing their excitability (Freund & Katona, 2007). Membrane proteins like voltage-gated 
calcium channels (CaVs) and cannabinoid receptors modulate neurotransmitter release (Guo & 
Ikeda, 2004). CaVs permit calcium ions to enter the presynaptic terminal which facilitate vesicular 
fusion and neurotransmitter exocytosis. Cannabinoid receptors are coupled to CaVs and 
downregulate calcium ion entry when activated by cannabinoids (Zamponi & Currie, 2013). 
Additionally, CaVs modulate the intrinsic firing properties of P-cells by coupling to calcium-
activated potassium channels (Loane, Lima, & Marrion, 2007). There are multiple CaV and 
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cannabinoid receptor subtypes; the N-type calcium channel (CaV2.2) and the type-1 cannabinoid 
receptor (CB1) are known to regulate neurotransmitter release from CCK+INs in the hippocampus 
(Szabo et al., 2014). However, the role of CaV2.2 and CB1 in CCK+INs of the BLA and mPFC has 
not been described. In my master’s thesis, I aim to elucidate the role of CaV2.2 in CCK+IN/P-cell 
synapses in the BLA (CHAPTER 1) and determine if CB1 regulates neurotransmitter release in 
this system (CHAPTER 2). Additionally, I will assess the role of CaV2.2 in regulating GABA 
release and intrinsic firing properties in the infralimbic region of the mPFC (CHAPTER 3).   
 
The Role of Fear and Anxiety in Survival 
Emotions are thought to be the result of natural selection, as they prompt behavioral 
responses important for survival (Darwin, 1998). A critical emotion for survival, fear, is defined 
as a motivational state that promotes either defensive or escaping behaviors (Gherardi, McFarland, 
& Tinbergen, 1988). Exposure to fearful stimuli often correlates with learning. Animals (including 
humans) adapt behavioral changes to avoid repeat exposure to fear, particularly if the fearful 
stimuli are associated with pain or stress. Fear-related learning can manifest through a closely 
related emotion; anxiety (Steimer, 2002). Anxiety involves behavioral and physiological responses 
including avoidance, vigilance, and arousal, all intended to protect the animal from danger. While 
fear is focused on known dangerous stimuli, anxiety is often a directionless response to an 
unknown danger or internal conflict (Ritu, Sandeep, Mamta, & Nirja, 2013).  
 
Fear and Anxiety are Related to the Limbic System  
The limbic system, also known as the ‘emotional brain,’ was largely defined by James 
Papez (1937) and Paul MacLean (1955). Papez related brain areas like the cingulate cortex, 
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thalamus, hypothalamus, hippocampus, and with emotional patterns observed in human 
experiments. MacLean refined Papez’s work, highlighting the role of the prefrontal cortex and 
subcortical areas like the amygdala and septum in emotional experiences (J. LeDoux, 1996; Roxo, 
Franceschini, Zubaran, Kleber, & Sander, 2011). More than a series of brain structures, limbic 
areas form a functional system. Feelings of fear and anxiety are complex, involving more than just 
emotional components. For example, fear and/or anxiety-related stimuli are processed by the 
prefrontal cortex (PFC), which modulates physiological and behavioral responses (via the 
amygdala). The amygdala assimilates sensory, contextual, and cognitive information to influence 
fear extinction, anxiety-related behavior, and selective attention (J. E. LeDoux, 2009; Steimer, 
2002). The integration of cognitive, physiological, and sensory information in the BLA and PFC 
illustrates the complexity of fear and anxiety (J. E. LeDoux, 2009). 
 
The Role of the Medial Prefrontal Cortex in Anxiety  
The PFC is believed to influence the conscious experiences and thoughts related to anxiety 
(J. LeDoux, 1996; Steimer, 2002) as well as module anxiety-like behaviors (Sierra-Mercado, 
Padilla-Coreano, & Quirk, 2011). fMRI studies show changes in PFC activity in patients with 
anxiety disorders (generalized and post-traumatic), which are behaviorally characterized by the 
inability to control fear responses (Sierra-Mercado et al., 2011). Deficient recruitment of the PFC 
(ventromedial region) during fear inhibition is observed in patients with generalized anxiety 
disorder (Greenberg, Carlson, Cha, Hajcak, & Mujica-Parodi, 2013). Similarly, decreased 
activation of the PFC (ventromedial region) in response to trauma-related cues is present in 
patients with post-traumatic stress disorder (PTSD) (Shin et al., 2004). In animal research, similar 
observations have been made. Lesions to the rat PFC (right infralimbic region) were shown to have 
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anxiolytic effects and suppress autonomic nervous system responses (Sullivan & Gratton, 2002). 
In mouse models, the PFC is associated with fear-related learning and fear expression, both of 
which can be impaired with selective inactivation of PFC sub-regions (Sierra-Mercado, Corcoran, 
Lebrón-Milad, & Quirk, 2006; Sierra-Mercado et al., 2011) 
The rodent PFC is comprised of multiple sub-regions with specialized functions including 
the medial, lateral, and orbitofrontal cortices. The medial prefrontal cortex (mPFC) is the target of 
extensive anxiety research (Duvarci & Pare, 2014; Morgan, Romanski, & LeDoux, 1993; Sullivan 
& Gratton, 2002). Further divided, the mPFC is comprised into the anterior cingulate cortex (AC), 
the prelimbic cortex (PL), and the infralimic cortex (IL) (Figure 1) (Paxinos & Watson, 2007). 
The IL and PL play unique roles in anxiety-related processing and differentially connect to the 
amygdala. The IL facilitates the storage of extinction learning in target structures (Do-Monte, 
Manzano-Nieves, Quinones-Laracuente, Ramos-Medina, & Quirk, 2015). IL-BLA connections 
are involved in the extinction of 
conditioned fear (Ferreira et al., 
2015; Sierra-Mercado et al., 2011). 
Excitatory neurons in the PL project 
to the BLA and are involved in the 
expression of fear (Sierra-Mercado 
et al., 2011; Wang et al., 2015). In 
rodents, fear is expressed by 
behaviors like freezing. An animal 
that displays reduced explorative 
behaviors or excessive grooming is 
Figure 1| Regions of the mouse medial prefrontal cortex. A 
Nissl stained coronal section of the mouse brain containing the 
PFC is paired with a stereotaxic atlas depiction of the subdivisions 
of the mPFC. AC, anterior cingulate; PL, prelimbic; IL, 
infralimbic. Adapted from Michelsen et al., 2007; Paxinos & 
Watson, 1998; Allen Mouse Brain Atlas. 
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considered to be exhibiting anxiety-like behavior. Stressful stimuli activate the PL and increase 
fear expression and anxiety-like behaviors (Hurley, Herbert, Moga, & Saper, 1991; Sullivan & 
Gratton, 2002), while selective inactivation of the PL reduces them (Sierra-Mercado et al., 2011). 
Abnormal activity in the connections from the PL and IL to the BLA can prompt inappropriate or 
deficient response to fear (Greenberg et al., 2013), a characteristic common to anxiety disorders. 
 
The Role of the Amygdala in Processing Fear and Anxiety  
The amygdala is an almond-shaped, highly interconnected limbic system structure 
implicated in the behavioral output of anxiety. Amygdalar functions and connections are conserved 
across many species, suggesting that research findings in animal models like the mouse (Mus 
musculus) may have human implications (Janak & Tye, 2015). For non-human primates, lesions 
to the amygdala impair their ability to associate a stimulus with positive/non-harmful or 
negative/potentially harmful outcomes (Weiskrantz, 1956) and lead to hypo-emotionality 
(Aggleton & Passingham, 1981). In rodents, the amygdala facilitates behavioral responses (i.e. 
freezing/playing dead in front of predator) by integrating rapid sensory input (i.e. visualization of 
a predator) from the thalamus and slower sensory input (i.e. motivation to escape the predator) 
from the prefrontal cortex (Steimer, 2002). Furthermore, the amygdala influences cognition, 
perception, and associative learning (J. E. LeDoux, 2009; Steimer, 2002). In associative learning, 
an animal relates a new response to a particular stimulus, or one stimulus to a second stimulus 
(Janak & Tye, 2015). In humans, (Anderson & Phelps, 2001) and rats (Blanchard & Blanchard, 
1972), damage to the amygdala hinders the ability to recognize fearful stimuli. Amygdalar 
dysfunction is also caused by disruptions in the balance of excitatory and inhibitory signaling. 
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These disruptions are observable in anxiety disorders (Etkin, Prater, Schatzberg, Menon, & 
Greicius, 2009). 
The amygdala is composed of several nuclei, including the basolateral amygdala (BLA) 
and the central amygdala (CeA) (Figure 2). The BLA is further comprised of the basal amygdala 
(BA) and lateral amygdala (LA), and is the main source of excitatory output to other brain regions 
involved in fear and anxiety. Thalamic and cortical sensory signals project to the LA, which 
connects to the BA and CeA (Keifer, Hurt, Ressler, & Marvar, 2015). Direct stimulation of the 
BLA is correlated with anxiety-like behavior (Johansen et al., 2010). The BLA can both upregulate 
and downregulate freezing behaviors through projections to the PL and IL, respectively, and is 
involved in anxiety-related memories via hippocampal connections (Sierra-Mercado et al., 2011). 
Opposite of the BLA, the CeA is mainly composed of inhibitory interneurons. Divided into the 
centromedial (CEm) and 
centrolateral amygdala (CEl), 
the CeA is involved in the 
translation of BLA signals to 
behavioral output (Janak & Tye, 
2015). It has been demonstrated 
that inhibition of BLA-CeA 
connections increases anxiety-
related behaviors while direct 
stimulation decreases them (Tye 
et al., 2011).  
 
Figure 2| Regions of the mouse amygdala. A Nissl stained coronal 
section of the mouse brain is paired with a diagram representing the 
amygdala nuclei. The basal (BA) and lateral (LA) nuclei comprise the 
basolateral amygdala (BLA) while the centromedial (CEm) and 
centrolateral (CEl) nuclei comprise the central amygdala (CeA). 
Adapted from Allen Mouse Brain Atlas; Keifer et al., 2015. 
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The Role of the Hippocampus in Anxiety-related Learning and Memory  
The HPC is divided into ventral and dorsal regions, each of which contains Cornu 
Ammonis (CA) regions (CA1 - CA4). Additionally, the CA regions contain a system of laminar 
organization (Figure 3). The stratum oriens (SO), stratum pyramidale (SP), stratum radiatum (SR), 
and stratum lacunosum-moleculare (slm) possess different cells, circuit organization, and functions 
in hippocampal processes. The ventral portion of the hippocampus (vHPC) is implicated in fear 
conditioning and anxiety-like behavior through its connections with the mPFC and BLA. BLA-
vHPC connections are necessary for forming memories of environmental context (Goosens, 2001; 
Maren & Fanselow, 1995), while vHPC-mPFC connections are required for retrieving memories 
when presented with specific context (Sierra-Mercado et al., 2011). Contextual memory and the 
memory retrieval process are important for the survival of a species, especially when the context 
involves perceived danger or negative emotions (Goosens, 2001). Chronic stress, fear, and anxiety 
Figure 3| Regions of the mouse hippocampus. A Nissl stained coronal section of the mouse brain 
is paired with a diagram detailing the regions and layers of the vHPC. CA, Cornu Ammonis; so, 
stratum oriens; sp, stratum pyramidale; sr, stratum radiatum; slm, stratum lacunosum-moleculare. 
Adapted from Allen Mouse Brain Atlas; Silva-Gómez, 2013; Paxinos & Watson, 1998. 
 9 
can disrupt these processes and result in a state of hippocampal dysfunction. There is evidence that 
hippocampal dysfunction is both a risk factor for developing and complication of anxiety disorders 
(Cominski, Jiao, Catuzzi, Stewart, & Pang, 2014).  
 
Cells and Circuits in Anxiety-related Brain Areas  
New and developing pharmacological treatments for anxiety disorders must aim to 
decrease activity in the neural circuits that influence anxiety and increase activity in those that 
reduce anxiety. Fundamental to these objectives is research which provides a more complete 
understanding of the molecular neuroanatomy of the limbic system and the functional 
neurophysiology of anxiety disorders. Communication between and within limbic system areas is 
facilitated by complex and highly organized neuronal circuits. Similar cell types and circuitry are 
thought to exist across limbic regions like the mPFC, BLA, and vHPC (Jinno, 2009). However, it 
is not understood if there are underlying functional differences in these circuits, nor what 
implications they might have in the neuronal processes of anxiety. 
The mPFC, BLA, and vHPC contain a mixture of excitatory (glutamatergic) pyramidal 
cells (P-cells) and inhibitory (GABAergic) interneurons (INs). P-cells are characterized by their 
piriform morphology, apical dendrites, and long axons which allow for communication across 
brain regions. INs innervate local P-cells and are classified by the domain in which they target. 
INs that target P-cell bodies (somas/somatas) are termed basket cells (BCs), those that target the 
axon initial segments are termed chandelier cells, and those that target dendrites are termed 
dendritic inhibitory cells (Freund, 2003). INs can be further categorized by identifying their 
intrinsic firing properties and neuropeptide content. Intrinsic firing properties, including action 
potential spike frequency and firing pattern, indicate how an IN behaves in a neuronal circuit 
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(Benda & Herz, 2003). Neuropeptide contents are used as a marker of IN subtypes, and indicate 
the neurotransmitters, receptors, and functions likely associated with a particular subtype. In the 
mPFC, BLA, and HPC, several subtypes of BCs have been identified for their unique roles in 
influencing P-cell activity (Barsy, Szabó, Andrási, Vikór, & Hájos, 2017; Freund, 2003; Whissell, 
Cajanding, Fogel, & Kim, 2015). BCs containing the neuropeptide parvalbumin (PV+BCs) 
process multiple converging stimuli and display fast, non-adapting firing patterns (Nyíri, 
Stephenson, Freund, & Somogyi, 2003). Cholecystokinin-containing BCs (CCK+BCs) respond to 
slow, asynchronous inputs and display moderate, adapting firing patterns (Bartos & Elgueta, 2012; 
Veres, Nagy, & Hájos, 2017). Understanding functional specifics about INs within limbic 
structures may help elucidate their complex role in mediating fear and anxiety. 
Descriptions of the wiring, innervation, and postsynaptic targets of INs requires a 
description of how IN/P-cell networks operate. Across P-cells and IN subtypes, there are variations 
in intrinsic firing and synaptic properties (Kullmann, 2011). In general, the synaptic events which 
excite INs are faster than those that excite P-cells. This is advantageous for controlling anxiogenic 
pathways, as excitation is under strict regulation by INs, particularly BCs (Deleuze, Pazienti, & 
Bacci, 2014). This regulation comes in multiple forms including feedforward inhibition. In 
feedforward inhibition, a local IN, excited by an afferent projection, delivers an inhibitory signal 
to a P-cell. Depending on the cellular properties of the IN, feedforward inhibition can limit the 
window for action potential generation or cancel out P-cell excitation (Jasnow, Ressler, Hammack, 
Chhatwal, & Rainnie, 2009). In addition to feedforward inhibition, there is feedback inhibition. 
The firing of P-cells activates INs, which in turn inhibit P-cells (Freund & Katona, 2007). Once 
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feedback and feedforward inhibition decline, 
P-cells are able to fire again. The combination 
of feedforward and feedback inhibition 
establish a neuronal oscillation, also known as 
a brainwave (Möhler, 2002). A prominent form 
of inhibition in the BLA and mPFC is known as 
perisomatic inhibition (Figure 4), wherein 
CCK+BCs and PV+BCs synchronize the 
activity of local P-cells (Freund & Katona, 
2007). The synapses made in perisomatic 
inhibitory are highly modifiable by ion 
channels, neurotransmitters, and additional extracellular messengers, prompting a closer review of 
their underlying molecular components of in anxiety-implicated circuits of the vHPC, mPFC, and 
BLA.  
In the vHPC, excitatory signaling is transmitted through P-cell projections from CA3 to 
CA1. Anxiety research often targets CA3 and CA1, as these sub-regions are major output pathways 
to other limbic areas. Several networks of INs exist within these output pathways which can 
modulate P-cell activity (Kullmann, 2011). These include fast-spiking PV+BCs, regular-spiking 
CCK+BCs, chandelier INs, and Schaffer collateral-associated (SCA) INs (Kullmann, 2011). 
Research has shown that while PV+BCs are more abundant overall, CCK+BCs outnumber 
PV+BCs in several sub-regions of the hippocampus (Whissell et al., 2015). The most superior 
layer of the vHPC, the SO, contains BC bodies and the basal dendrites of P-cells, whose cell bodies 
are located the second-most superior layer, the SP (Lacaille & Williams, 1990). The SP is 
Figure 4| Perisomatic inhibition. Simplified circuit 
diagram depicting perisomatic inhibition of a 
pyramidal cell by parvalbumin (PV+) and 
cholecystokinin (CCK+) containing basket cell 
interneurons (INs). Adapted from Deleuze et al., 
2014. 
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recognizable by its dense P-cell composition and role in hippocampal output. BCs can be found in 
the SP as well; their proximity to P-cells illustrates their known role in perisomatic inhibition (Neu, 
Földy, & Soltesz, 2007; Whissell et al., 2015). The layer immediately following the SP, the SR, 
contains P-cell projections from CA3 to CA1, termed the Schaffer collaterals. Schaffer collaterals 
are the topic of extensive neuropsychiatric research, as they are critical for long-term potentiation 
and emotional memory (Kumar, 2011; Stanton, Winterer, Zhang, & Müller, 2005). BCs in CA1 
are innervated by Schaffer collaterals, while the dendrites of Schaffer collaterals themselves are 
innervated by SCA INs (Kullmann, 2011). 
Similar to the SP layer of the vHPC, the mPFC contains mostly P-cells (80-90%) with a 
minority of INs (10-20%) spread heterogeneously across a system of laminar organization. In the 
human brain, there are six layers (L1-L6) while in rodents there are only five (rodents do not 
possess L4) (Heidbreder & Groenewegen, 2003). Across layers, composition and connectivity vary, 
but functional characteristics of IN/P-cell connections are relatively conserved. INs wield strong, 
differential control over local circuitry and are able to synchronize P-cell spiking throughout the 
mPFC (Sparta et al., 2014). In rodents, cells located in L1 are thought to be exclusively GABAergic 
INs (Riga et al., 2014). L1 INs receive excitatory input from the thalamus and facilitate dendritic 
inhibition of L2/3 P-cells (Cruikshank et al., 2012). BC/P-cell perisomatic inhibitory networks are 
seen in L2/3 and L5. P-cells in L2/3 and L5 receive excitatory inputs from the thalamus, the 
contralateral mPFC, the vHPC, and the BLA. These P-cells project to various brain areas 
depending their location within the mPFC. In the PL, L2/3 P-cells projects to the BLA, while in 
the IL, L2/3 and L5 P-cells project to the BLA (Ferreira et al., 2015; Zaitsev, Povysheva, Gonzalez-
Burgos, & Lewis, 2012). P-cells in L2/3 of the PL are involved in fear expression while P-cells in 
L2/3 and L5 of the IL are involved in the extinction of conditioned fear (Figure 5) (Sierra-Mercado 
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et al., 2011). It is vital to make these distinctions, as they demonstrate that even within L2/3 of the 




The BLA is comprised of P-cells and multiple IN subtypes including PV+BCs and 
CCK+BCs (Ehrlich et al., 2009; Freese & Amaral, 2005). P-cells receive inhibitory input from 
local BCs and excitatory input from cortical areas via the external capsule (EC), a white matter 
fiber tract containing clusters of P-cell axons (Little & Carter, 2013). Excitation of P-cells in the 
BLA correlates with anxiety-like behavior (Johansen et al., 2010). Perisomatic inhibition, 
facilitated by CCK+BCs and PV+BCs, has been observed in electrophysiology recordings from 
P-cells in the BLA (Freund, 2003). PV+BCs and CCK+BCs receive excitatory signals from local 
and distant P-cells (via the EC) and inhibitory signals from local INs (Faber, Callister, & Sah, 
2001; Rainnie, Asprodini, & Shinnick-Gallagher, 1993). Studies have been performed on the 
Figure 5| Basic neural connections implicated in fear. Left: The circuitry involved in fear expression. 
Emotional memories from the hippocampus (HPC) interact with the prelimbic cortex (PL) which regulates 
behavioral output via the amygdala (BLA and CeA). Right: The circuitry involved in fear extinction. The 
HPC and basolateral amygdala (BLA) interact with the infralimbic cortex (IL) to facilitate fear extinction. 
Behaviors reflective of fear extinction are produced by the IL via the extended amygdala (ITC) and central 
amygdala (CeA). Neuronal plasticity associated with extinction learning is represented in pink. Adapted 
from Sierra-Mercado et al., 2011. 
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underlying molecular components of perisomatic inhibitory synapses in the vHPC, however less 
is known regarding similar circuits in the BLA (Barsy et al., 2017; Freund & Katona, 2007; 
Trouche, Sasaki, Tu, & Reijmers, 2013). Functional studies on neurotransmitter release in BC/P-
cell synapses are needed to understand how behavioral output associated with anxiety is regulated 
in the BLA. 
 
The Neurochemical Correlates of Anxiety - GABA and Glutamate 
Neuronal circuits in the BLA, mPFC, and vHPC possess extensive γ-aminobutyric acid 
(GABA) and glutamate neurotransmitter systems (Bystritsky, Khalsa, Cameron, & Schiffman, 
2013). GABA is the principle inhibitory neurotransmitter in the brain while glutamate is the 
principle excitatory neurotransmitter. Balance between GABAergic and glutamatergic activity is 
critical for normal fear and anxiety-related processing (Möhler, 2002). Excess GABAergic activity 
can be anxiolytic but can also impair cognition. Insufficient GABAergic activity can result in 
increased anxiety (Möhler, 2002). Chronic deficits in GABAergic activity contribute to the 
pathophysiology of anxiety disorders; anti-anxiety medications including benzodiazepines and 
gabapentinoids enhance GABAergic activity (Sills, 2006). Alterations to glutamate transmission 
have also been shown to be effective in augmenting anxiety disorders (Dawson & Watson, 2009), 
as glutamate is involved in the pathways underlying normal and pathological anxiety states 
(Bystritsky et al., 2013).  
 The effects of neuronal inhibition differ across cell types, circuits, and brain areas. When 
P-cells are inhibited, they no longer release glutamate onto their projection targets. On the contrary, 
inhibition of INs prevents IN-mediated inhibition; resulting in P-cell disinhibition (Andrási et al., 
2017). Accordingly, it is important to examine neuronal inhibition at the cellular and circuit level 
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to more readily understand its implications in anxiety. GABA binds to the GABAA receptor, a 
ligand-gated ion channel. Upon binding, the channel opens and chloride (Cl-) anions flow inward 
(U. Rudolph & Antkowiak, 2004). Chloride influx induces electrical events known as inhibitory 
postsynaptic currents and potentials (IPSCs and IPSPs). As a result, hyperpolarization, action 
potential inhibition, and decreased neurotransmitter release occur (Amir, Michaelis, & Devor, 
1999). GABAA receptors are widespread, expressed in multiple cellular domains (i.e. terminals, 
somas, and axons) and cell types not exclusively involved in anxiety (Freund, 2003; Freund & 
Katona, 2007). In addition to the GABAergic system, the glutamatergic system regulates anxiety-
related neuronal output from P-cells. 
 Proper glutamatergic transmission is required for anxiety states (Bystritsky et al., 2013). 
The glutamate receptors most pertinent to anxiety-related circuits are the AMPA and NMDA 
subtypes. As a whole, glutamatergic activity shows cell-type specific dynamics in modulating 
anxiety-related neuronal output (Nyíri et al., 2003). For example, long-term potentiation, 
implicated in storage of traumatic memories, relies on the NMDA receptors within Schaffer 
collaterals of the hippocampus (Harris & Cotman, 1986). Additionally, AMPA receptors on P-cells 
in the BLA are redistributed from dendritic stores into spines following severe stress (Hubert, Li, 
Rainnie, & Muly, 2014).  
 
Molecular Components of GABAergic and Glutamatergic Neurotransmission 
GABA and glutamate neurotransmission are modulated by G protein-coupled receptors 
(GPCRs) and voltage-gated calcium channels (CaVs). Located in the transmembrane domain, 
GPCRs are signal transduction proteins which interact with molecules in the extracellular and 
intracellular environment, as well as other transmembrane receptors (Trzaskowski et al., 2012). 
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There are numerus families and subtypes of GPCRs which couple to different subunits. GPCRs in 
the mPFC, vHPC, and BLA are coupled to the Gi alpha subunit (Gαi), including metabotropic 
GABA and glutamate receptors (Lee et al., 2015; Lenkey et al., 2015; Talani & Lovinger, 2015; 
Zoppi et al., 2011). These GPCRs are involved in a variety of anxiety-related physiological 
processes including behavior and mood regulation (Swanson et al., 2005). For this reason, Gαi 
receptors are the target of several pharmaceutical anxiety treatments. Gαi receptors are activated by 
ligand binding (whether endogenous or synthetic) and exert an inhibitory effect on cAMP and 
calcium, two major internal singling molecules. As a result, calcium-mediated processes and 
cAMP-dependent signal transduction pathways are inactivated (Scotter, Graham, & Glass, 2009). 
Fundamentally, CaVs are protein complexes consisting of several subunits (α1, β, α2δ, and 
γ) which mediate calcium ion entry into a cell (Figure 6). There are two distinct classes of CaVs 
based on their voltage-gating properties; high voltage-activated (HVA) and low voltage-activated 
(LVA). The phrase ‘voltage-gated’ is derived from the closed state of these channels under resting 
membrane potential conditions. 
Only a strong enough membrane 
depolarization (i.e. an action 
potential) will release this voltage-
gate (Stotz, 2001). Within each 
class of CaV, subtypes are 
determined by the α1 subunit. The 
importance of the α1 subunit cannot 
be stressed enough, as it forms the 
calcium-selective ion channel 
Figure 6| Schematic of a voltage-gated calcium channel 
complex. CaVs are composed of a pore-forming subunit (α1) and 
several ancillary subunits. The α1 subunit functions as a voltage 
sensor, binding site, and permeable ion channel. The β subunit 
provides stability and modulates activation of α1. The α2δ subunit 
enhances expression and regulation of α1. The γ subunit is not well 
understood but does not appear to regulate channel function. 
Adapted from Marrero-Rosado et al., 2014; Hannon & Atchison, 
2013. 
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through which calcium enters the cell (Williams et al., 1992). The α1 subunit can detect changes 
in membrane potential and contains binding sites for pharmaceutical antagonists (Catterall, 2011; 
Zamponi, 2016). From ten known α1 subunits there are five known CaV isoforms. The isoforms 
and their respective α1 subunit encoding genes (in parenthesis) are as follows: L-type (CaV1.1, 
CaV1.2, CaV1.3, CaV1.4), P/Q-type (CaV2.1), N-type (CaV2.2), R-type (CaV2.3), and T-type 
(CaV3.1, CaV3.2, CaV3.3) (Catterall, 2011). The remaining CaV subunits serve α1; enhancing its 
expression (δ), stabilizing its conformation (β), and regulating its activation and inactivation 
kinetics (β, α2δ) (Hannon & Atchison, 2013). 
Of the numerous α1 subunits, those encoded by CaV2.1, CaV2.2, and CaV2.3 (P/Q-, N-, and 
R-type channels) are most involved in mediating signal transduction in GABAergic and 
glutamatergic cells (Catterall, 2011; Zamponi, 2003). Additionally, CaV2 channels have been 
shown to modulate neuronal firing through coupling to calcium-activated potassium channels 
(Alviña & Khodakhah, 2008; Loane et al., 2007). During membrane depolarization, CaV2 opens 
and allows calcium entry into the neuron, which induces numerous physiological events. For 
instance, calcium interacts 
with SNARE proteins to 
fuse neurotransmitter 
vesicles to the presynaptic 
terminal, where subsequent 
exocytosis leads to synaptic 
transmission (Südhof, 
2012). It has been 
demonstrated that calcium 
Figure 7| Proposed mechanism of 
CaV2.2-mediated anxiogenic 
signaling. Anxiety-related signaling 
is propagated by excitatory pathways 
in areas like the vHPC and BLA. 
Action potentials travel down the 
presynaptic axon and into the 
terminal, whereby CaV2.2 is 
activated and calcium (Ca2+) enters 
the cell. Neurotransmitters (blue 
circles) are released into the synapse 
and activate Ca2+ entry through 
postsynaptic glutamate (Glu) 
receptors. Increased Ca2+ 
concentration further propagates 
anxiogenic signaling through the 
postsynaptic cell and beyond. 
Adapted from Schmidtko et al., 2010; 
Hannon & Atchison, 2013. 
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entry through CaV2.1 and CaV2.2 channels initiates the release of glutamate and GABA in fast 
synapses. More specifically, it has been discovered that CaV2.2 channels regulate GABA release 
from presynaptic CCK+INs in the vHPC (Szabo et al., 2014). Given the role of CCK+INs in 
perisomatic inhibition of P-cells, and the role of excess P-cell activity in anxiety-related behaviors 
(Figure 7), CaV2.2 channels are a critical research target for anxiety disorders (Kurihara & Tanabe, 
2003; Lee et al., 2015; Lee, 2013; Szabo et al., 2014).  
 
Modulation of the N-type Channel and Anxiety Implications  
CaV2.2 modulation is a current target for treating neuropathic pain (Hannon & Atchison, 
2013) and has emerged as a possible means of treating anxiety (Newton & Messing, 2009). 
Previous studies have found that mice lacking CaV2.2 display reduced anxiety levels (Saegusa, 
2001), and current research aims to dissect the role CaV2.2 blockers play in anxiety. In nature, a 
highly-specific CaV2.2 blocker is found in the venom of the cone snail, Conus magus. Known as 
‘w-Conotoxin GIVA’ when isolated, this peptide neurotoxin show affinity only for CaV2.2 
(McCleskey et al., 1987). Zinconotide and Leconotide, synthetic w-Conotoxins used to treat 
neuropathic pain, have strong yet poorly-understood anxiety correlates (Kolosov, Aurini, Williams, 
Cooke, & Goodchild, 2011; Schmidtko, Lötsch, Freynhagen, & Geisslinger, 2010; Scott, Wright, 
& Angus, 2002). The GABA analogue drugs Gabapentin and Pregabalin have seen increasing off-
label use to treat anxiety disorders. Typically used to treat seizures and nerve pain, Gabapentin and 
Pregabalin target the α2δ subunit, indirectly modulating CaV2.2 (Sills, 2006). By modulating 
CaV2.2, the side effects associated with GABA modulation (i.e. benzodiazepines) can be bypassed. 
It is important to state that these drugs are not approved as a primary treatment for anxiety disorders. 
However, the increasing and successful use of CaV2.2 modulators in treating anxiety disorders 
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prompts research into their functional role in anxiety-related neuronal circuits (Lee, 2013; Lotarski 
et al., 2011). 
CaV2.2 channels are modulated by a variety of GPCRs. One form of modulation is voltage-
dependent inhibition facilitated by the binding of the G beta-gamma complex (Gβγ) to the pore-
forming subunit of CaV2.2 channels (Ikeda, 1996). Two inhibitory mechanisms can occur as a 
result. In one mechanism, Gβγ induces a shift in the voltage-dependent activation properties of 
CaV2.2 channels, which then require larger-than-normal depolarizations to open (Zamponi & 
Currie, 2013). Alternatively, GPCRs can inactivate CaV2.2 through a ‘hinged lid’ mechanism, 
closing the ion channel-forming subunit, a1 (Stotz, 2001). In either mechanism, calcium entry 
through CaV2.2 is limited or blocked, and subsequent neurotransmitter release from presynaptic 
terminals is inhibited. There are a wide variety of GPCRs that exhibit inhibitory effects on CaVs, 
but a specific family has been shown to extensively couple with CaV2.2 in anxiety-related brain 
areas. Cannabinoid receptors, part of the endocannabinoid system, are a specific family of 
primarily Gαi GPCRs heavily implicated in anxiety (Haller, Bakos, Szirmay, Ledent, & Freund, 
2002).  
 
The Endocannabinoid System and Anxiety  
The endocannabinoid (eCB) system is a network of primarily Gαi GPCRs and ligands 
known to modulate synaptic transmission throughout the brain. Of the two cannabinoid receptor 
types (CB1 and CB2), CB1 is the major synaptic constituent of the eCB system, heavily expressed 
in CCK+INs (Lutz, Marsicano, Maldonado, & Hillard, 2015). CB1 is activated by endogenous 
cannabinoid molecules like anandamide (AEA) and 2-arachidonoylglycerol (2-AG), as well as 
exogenous cannabinoids like THC (Pagotto, Marsicano, Cota, Lutz, & Pasquali, 2006). 
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Cannabinoids act as retrograde feedback 
inhibition messengers; postsynaptic cells 
synthesize 2-AG/AEA, which bind to CB1 
receptors on the presynaptic terminal, 
suppressing neurotransmitter release 
(Figure 8). CB1-mediated inhibition occurs 
in two general forms; phasic and tonic. 
Phasic inhibition occurs as a result of 
postsynaptic depolarization, thus is 
generated in response to specific 
postsynaptic signals. Tonic inhibition is the 
result of basal CB1 activity, and occurs 
irrespective of postsynaptic signals (Lee et al., 2015; Soltesz et al., 2015). Mechanistically, CB1 
modulates neurotransmitter release by coupling to and downregulating CaVs (Wilson, Kunos, & 
Nicoll, 2001). By inhibiting calcium entry through CaVs, processes like vesicular fusion are 
prevented (Catterall, 2011). In the CA3 region of the vHPC, CB1 was shown to specifically couple 
to CaV2.2, but it is not known if this coupling is conserved in the BLA. 
The eCB system has been shown to differentially modulate synaptic transmission across 
different brain regions, cell types, and synapses. Heavy integration of the eCB system has been 
observed in the HPC, PFC, and amygdala, where it is thought to have modulatory effects on fear 
and anxiety processing (Lutz et al., 2015). At GABAergic synapses, eCB-mediated inhibition is 
known as depolarization-induced suppression of inhibition (DSI), and in glutamatergic synapses, 
it is known as depolarization-induced suppression of excitation (DSE) (Ramikie & Patel, 2012). 
Figure 8| eCB-mediated feedback inhibition system in 
CA3. Calcium (Ca2+) entry through CaV2.2 in the 
postsynaptic P-cell induces anandamide synthesis. 
Anandamide binds to cannabinoid receptor 1 (CB1) on the 
presynaptic cholecystokinin interneuron (CCK+IN) 
terminal. Ca2+ entry though CaV2.2 is then inhibited, 
preventing GABA release. Adapted from Sharkey & 
Pittman, 2005.  
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DSI and DSE are short-term effects, as eCB-mediated synaptic modulation follows a negative-
feedback loop. Neurons containing CB1 are classified into two groups; high CB1-expressing cells, 
which are sparsely distributed in the BLA and cortical areas, and low CB1-expressing cells, which 
are more evenly dispersed (Marsicano & Lutz, 1999; Yoshida et al., 2011). Research on cell-
specific CB1 expression has revealed high selectivity for CCK+INs over other INs. In the BLA, 
95% of high CB1-expressing cells and 90% of low CB1-expressing cells were CCK+INs 
(Marsicano & Lutz, 1999). Contrarily, CB1 expression is largely absent from PV+INs. In addition 
to CCK+IN selectivity, CB1 has been shown to couple with CaV2.2. In rat sympathetic neurons, 
N-type calcium currents were inhibited by CB1 agonists, inhibition which was then reversed by 
CB1 antagonists (Guo & Ikeda, 2004). Furthermore, CB1-CaV2.2 coupling appears to be prevalent 
in CCK+INs. In the CA3 region of the vHPC, CaV2.2-dependent GABA release from CCK+IN 
terminals was shown to be inhibited with CB1 agonists (Szabo et al., 2014).  
It is widely accepted that there is a strong correlation between the eCB system and anxiety, 
but this correlation is not fully understood (Lutz et al., 2015). eCB system modulation shows 
potential for treating anxiety disorders, a well-known example of which being the anxiolytic 
properties of THC (Onaivi, Green, & Martin, 1990). In both humans and rodents, it has been shown 
that cannabinoids can influence anxiety-like symptoms in a biphasic manner; low doses produce 
anxiolytic effects while high doses produce anxiogenic effects (Moreira, Grieb, & Lutz, 2009; Rey, 
Purrio, Viveros, & Lutz, 2012). Research suggests that CB1 modulation has opposite effects on 
anxiety-like behavioral output in glutamatergic and GABAergic cells. Knockout mice lacking CB1 
in all glutamatergic cells show increased anxiety-like behaviors, while knockout mice lacking CB1 
in all GABAergic cells show reduced anxiety-like behaviors (Häring, Kaiser, Monory, & Lutz, 
2011). CB1-mediated anxiety effects are not confined to GABAergic and glutamatergic activity 
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however, and are different when isolating specific brain regions (Rovira-Esteban et al., 2017; 
Szabo et al., 2014). Accordingly, more detailed neurophysiological research must be conducted on 
the role of CB1 in cell populations and brain regions implicated in anxiety. 
 
Implications of CCK and CCK+INs in Anxiety  
CCK and CCK+INs have well-established links to anxiety which originate from their role 
in neuronal circuits. CCK, the CCK receptor (CCKB), and CCK+INs are highly expressed in the 
limbic system (Vanderhaeghen, Signeau, & Gepts, 1975). As a neuropeptide, CCK is found in 
vesicles and displays synaptic properties similar to classical neurotransmitters (Emson, Lee, & 
Rehfeld, 1980). CCK is associated with anxiety through its interactions with CCKB. In healthy 
patients, CCK administration induces panic attacks (Montigny, 1989) while CCKB antagonists 
block these panicogenic effects (Bradwejn, Koszycki, Couetoux du Tertre, van Megen, & et al., 
1994). In rodents, CCK agonists produce anxiety-like behaviors (Frankland, Josselyn, Bradwejn, 
Vaccarino, & Yeomans, 1996) while CCKB antagonists attenuate them (Josselyn et al., 1995). 
Binding of CCK to CCKB has been shown to modulate the neuronal properties of classical 
neurotransmitters (Altar & Boyar, 1989). Interactions exist between CCK and GABA, dopamine, 
and endocannabinoid neurotransmission (Altar & Boyar, 1989; Chhatwal et al., 2009; Lanza & 
Makovec, 2000).While these interactions remain relatively understudied, they represent potential 
underlying mechanisms by which CCK is linked to anxiety.  
CCK+INs display a distinct regulatory role over anxiety-like behaviors. Along with 
PV+INs, CCK+INs establish GABAergic connections onto the soma of P-cells in several brain 
regions including the BLA, HPC, and PFC (Freund & Katona, 2007; Sparta et al., 2014). In the 
BLA, CCK+INs innervate up to eight hundred P-cells each (Vereczki et al., 2016), and are thought 
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to prevent anxiety-like responses from occurring in non-threatening situations (Freund, 2003; 
Mascagni & McDonald, 2003; Truitt et al., 2009). When CCK+INs in the BLA are lesioned, rats 
display increased anxiety-like behaviors (Truitt et al., 2009), a phenotype thought to be the result 
of lost GABAergic and CCKergic activity. Additionally, it has been proposed that by acting with 
the eCB system, CCK+INs modulate fear inhibition and extinction (Bowers, Choi, & Ressler, 
2012). CCK+INs likely modulate fear extinction at the level of the BLA by inhibiting ‘extinction’ 
neurons (Duvarci & Pare, 2014). CCK+IN synapses are remodeled by fear extinction, displaying 
increased CB1 expression and thus decreased inhibition of extinction neurons (Duvarci & Pare, 
2014; Trouche et al., 2013). Given their expression of CaV2.2 and CB1, role in perisomatic 
inhibition, as well as integration in limbic system structures, CCK+INs are essential targets for 
anxiety research. 
 
Master’s Thesis Research  
Research Motivations  
We are motivated to determine the role of CaV2.2 in GABA release from CCK+INs onto 
P-cells in the BLA. It has been demonstrated in the CA3 region of the HPC that GABA release in 
CCK+IN/P-cell synapses is eliminated by blocking CaV2.2 (Szabo et al., 2014). If conserved, 
CaV2.2 may be a potential target for mediating anxiety at the level of the amygdala. Additionally, 
we are motivated to determine the role of CB1 in CCK+IN/P-cell synapses in the BLA. Given 
findings which indicate CB1 inhibits CaV2.2 and subsequently GABA release from CCK+INs onto 
P-cells in the HPC (Szabo et al., 2014), we are interested in examining this system in the BLA. 
CB1 shows promise in the development of novel anxiety treatments, but a greater understanding 
of its role in anxiety-related circuits is needed. Research describing the role of the IL in fear 
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extinction and its connections to the BLA motivates us to determine if CaV2.2 regulates presynaptic 
transmitter release and intrinsic firing properties in this region of the mPFC. P-cells in the mPFC 
receive dendritic inhibition from INs in superficial layers and perisomatic inhibition from proximal 
BCs (Riga et al., 2014). However, little is known about the role of CaV2.2 in regulating GABA 
release in these inhibitory synapses.  
 
Research Questions 
Chapter 1: Is GABA release in CCK+IN/P-cell synapses in the BLA CaV2.2-dependent? 
P-cells carry the bulk of information from the BLA to other brain areas implicated in anxiety. 
Previous research shows that excitation of P-cells in the BLA increases anxiety-like behaviors 
(Johansen et al., 2010). Local INs expressing the peptide cholecystokinin (CCK+INs) synapse onto 
the soma of P-cells, forming a system of perisomatic inhibition (Freund, 2003). Previous studies 
in the CA3 region of the HPC have shown that the GABA release from CCK+INs onto P-cells is 
dependent on CaV2.2 (Szabo et al., 2014). If this circuitry is conserved in the amygdala, Cav2.2 
could be a potential pharmacological target for regulating anxiety at the level of the BLA.  
Chapter 2: What is the role of CB1 in CCK+IN/P-cell synapses in the BLA? Does CB1 
exhibit tonic and/or phasic inhibition of GABA release? The eCB system and anxiety-like behavior 
are strongly correlated (Lutz et al., 2015). Similarly, P-cell excitability in the BLA is correlated 
with anxiety-like behavior (Davis, Rainnie, & Cassell, 1994). CB1 has been shown to inhibit 
neurotransmitter release in both glutamatergic and GABAergic synapses (Azad, 2003) in both 
ligand dependent (tonic) and independent (phasic) manners (Farrant & Nusser, 2005; Neu et al., 
2007; Roberto et al., 2010). When GABA release is suppressed, P-cells are disinhibited and more 
excitable. In the hippocampus, CB1 is present in and regulates transmitter release in CCK+IN/P-
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cell synapses (Yoshida et al., 2011). We are interested if this circuitry is conserved in the amygdala, 
and by what means (phasic and/or tonic) CB1 mediates GABA release from CCK+INs onto P-cells 
in the BLA.  
Chapter 3: Is transmitter release in IN/P-cell synapses in the IL CaV2.2-dependent? Is 
GABA release in CCK+IN/P-cell synapses in the IL CaV2.2-dependent? Are intrinsic firing 
properties of P-cells in the IL regulated by CaV2.2? Calcium channel physiology is relatively 
understudied in the infralimbic area of the mPFC. Our initial goal is to determine if, and to what 
degree, CaV2.2 is present in presynaptic IN inputs onto P-cells in the IL. Upon determining the 
role of CaV2.2 in IN terminals, we will specifically target CaV2.2 in CCK+INs. Comparisons can 
be drawn about the properties of this IL circuit to those in the BLA and HPC. We are also interested 
in determining if CaV2.2 modulates the intrinsic firing properties of P-cells in the IL. CaV2.2 makes 
a significant contribution to intrinsic firing properties of P-cells in the cerebellum (Alviña & 
Khodakhah, 2008), and couples to calcium-activated potassium channels in the HPC to modulate 
the after-hyperpolarization phase of action potentials (Loane et al., 2007).  
 
Summary of Findings  
 Chapter 1: I present fluorescence images depicting CCK+IN expression in the BLA as 
well as electrophysiological data on the role of CaV2.2 in CCK+IN/P-cell synapses. Cells were 
exposed to a CaV2.2 antagonist (ω-Conotoxin GIVA), following which IPSC peak amplitude 
decreased by an average of 51%. Results demonstrate that the release of GABA in CCK+IN/P-cell 
synapses in the BLA is partially CaV2.2-dependent.  
 Chapter 2: I present immunofluorescence images depicting CCK+IN and CB1 expression 
in the BLA and HPC, quantifying the level colocalization in each area. Second, I present 
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electrophysiology data on the sensitivity of GABA release in CCK+IN/P-cell synapses to phasic 
and tonic inhibition. A total of two cells were exposed to a CB1 agonist (2-AG) and antagonist 
(AM251). IPSC peak amplitude decreased by 26% following exposure to 2-AG and increased 34% 
following exposure to AM251. Results can be used to confirm the findings of Rovira-Esteban and 
colleagues (2017), who describe tonic and phasic CB1-mediated inhibition of transmitter release 
in CCK+IN/P-cell synapses in the BLA. 
 Chapter 3: I present electrophysiological data on the role of CaV2.2 in regulating GABA 
release from general INs, GABA release from specifically CCK+INs, and in P-cell intrinsic firing 
properties in the IL. Following exposure to ω-Conotoxin GIVA, IPSC peak amplitude in IN/P-cell 
synapses decreased an average of 46% across six cellular recordings. In CCK+IN/P-cell synapses, 
IPSC peak amplitude decreased an average of 9% over eight cellular recordings in response to ω-
Conotoxin GIVA. Additionally, ω-Conotoxin GIVA did not significantly affect the firing pattern 
and spike frequency of P-cells. These results can be used to demonstrate that 1) GABA release 
from INs in the IL is partially CaV2.2-dependent, 2) GABA release from CCK+INs in the IL is not 
significantly CaV2.2-dependent, and 3) P-cell firing properties are not significantly modulated by 
CaV2.2 in the IL.   
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CHAPTER 1: CAV2.2-MEDIATED GABA RELEASE FROM CCK+ INTERNEURONS 
ONTO PYRAMIDAL CELLS IN THE BASOLATERAL AMYGDALA 
 
Abstract 
The basolateral nucleus of the amygdala (BLA) is an interconnected limbic system structure 
implicated in anxiety. Normal function of the BLA relies on a balance between excitatory and 
inhibitory signaling, which is known to be disrupted in anxiety disorders like post-traumatic stress. 
Excitatory activity in the BLA is facilitated by glutamatergic pyramidal cells (P-cells), which when 
directly stimulated produce anxiety-like behavior. P-cells are regulated by inhibitory signaling 
from local interneurons (INs) including those that contain the neuropeptide cholecystokinin 
(CCK+). It has been demonstrated that CCK+INs regulate anxiety-like behavior at the level of the 
BLA, likely due to their inhibitory control over local neuronal circuits. The release of inhibitory 
neurotransmitter (GABA) from CCK+INs is regulated by voltage-gated calcium channels (CaVs), 
of which there are multiple subtypes. In the hippocampus, GABA release from CCK+INs is 
entirely dependent on the N-type calcium channel (CaV2.2). It is not known if this role of CaV2.2 
is conserved in the BLA, representing a potential target by which inhibition of anxiety-related 
output from the BLA is regulated. In this study, we determined the role of CaV2.2 in GABA release 
in CCK+IN/P-cell synapses in the BLA. To visualize the neuroanatomy of CCK+INs, a triple 
transgenic mouse model (CCK-Dlx5/6-tdT) was generated which labelled CCK+INs with red 
fluoresce (via the tdTomato fluorophore). To evoke GABA release from CCK+INs, a second triple 
transgenic mouse model (CCK-Dlx5/6-ReaChR) was generated in which CCK+INs express red-
activatable channelrhodopsins. Following optogenetic stimulation, inhibitory postsynaptic 
currents (IPSCs) were recorded in P-cells. The sensitivity of GABA release to CaV2.2 block was 
determined through bath addition of w-Conotoxin GIVA (CTX). Following CaV2.2 block, average 
IPSC peak amplitude decreased by 51% (n = 7 cells, SD = 14%, SEM = 5%) compared to control 
conditions, which was determined to be statistically significant (p = 0.0046, one-tailed paired t-
Test). Our results indicate that GABA release from CCK+INs in the BLA is partially CaV2.2-
dependent, contrasting total CaV2.2-dependency reported in the hippocampus. We propose that 
CCK+IN/P-cell synapses are differentially regulated by CaV2.2 in the BLA and hippocampus. As 
a result, CaV2.2 modulation likely has region-specific implications in anxiety. 
 
Introduction 
Fear is the result of an immediate, recognizable threat while anxiety is the result of 
perceived, imprecise threats (Steimer, 2002). Both fear and anxiety produce emotional, 
physiological, and behavioral changes intended for survival and are products of similar 
neurological activity. Anxiety can become dysfunctional however, occurring in inappropriate 
situations and causing disruptions to normal stimulus processing. This can manifest as anxiety 
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disorders in humans and anxiety-like behaviors in animal models. Common in both stations is 
abnormal activity in brain regions like the amygdala (Ritu et al., 2013). The amygdala is a critical 
brain region for fear-related learning and memory as well as anxiety-related behavioral output 
(Phelps et al., 2004; Roozendaal, McEwen, & Chattarji, 2009). Proper function of the amygdala 
requires balance between excitatory and inhibitory signaling. This balance is known to be 
disrupted by chronic anxiety and is observable in anxiety disorders like post-traumatic stress 
(PTSD) (Milad et al., 2009). The molecular components which regulate the balance between 
excitatory and inhibitory activity in the amygdala are not fully understood but serve as vital targets 
for anxiety research. 
The amygdala is composed of multiple nuclei with diverse functions and connections. The 
central amygdala (CeA), composed of the lateral nucleus (CeL) and medial nucleus (CeM), is 
considered an inhibitory mediator of the basolateral amygdala (BLA) (Capogna, 2014; Janak & 
Tye, 2015). The BLA, composed of the lateral nucleus (LA) and basal nucleus (BA), is considered 
the main source of excitatory neuronal output from the amygdala to brain regions involved in 
anxiety like the hippocampus (HPC) and prefrontal cortex (PFC) (Gale, 2004). The CeA is 
predominantly composed of GABAergic cells, containing both local and projection interneurons 
(INs). The cytoarchitecture of the BLA is similar to that of the PFC, as a majority (approximately 
80%) of neurons are glutamatergic pyramidal cells (P-cells) while a minority (approximately 20%) 
are GABAergic INs (Spampanato, Polepalli, & Sah, 2011). It is within the connections established 
between these two cell types that neuronal output is modulated. 
P-cells are known for their distinct piriform morphology, lengthy apical dendrites, and far-
reaching axonal projections. Within the BLA  and PFC, P-cells display similar intrinsic properties 
including regular spiking, non-adapting firing patterns and moderate spike frequency (Rainnie et 
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al., 1993). P-cells are targeted by several IN types (Freund, 2003); those which synapse onto the 
body of P-cells (soma) are termed basket cells (BCs) (Armstrong & Soltesz, 2012). BCs have a 
round morphology and branching dendrites that are involved in perisomatic inhibition in brain 
regions like the BLA, PFC, and HPC (Ferreira et al., 2015; Neu et al., 2007; Veres et al., 2017). 
Perisomatic inhibition is a form of feedback inhibition wherein P-cell activation stimulates the 
release of GABA from presynaptic BC terminals onto the P-cell body, suppressing excitatory 
activity (Freund & Katona, 2007). Subtypes of BCs, distinguishable by their firing patterns and 
neurochemical markers, differentially regulate P-cells through unique synaptic properties (Duvarci 
& Pare, 2014). Of particular interest to anxiety research are cholecystokinin-containing (CCK+) 
BCs.  
CCK is a neuropeptide with profound anxiogenic and panicogenic properties (Montigny, 
1989; Frankland et al., 1996; Rotzinger & Vaccarino, 2003). CCK+INs have been shown to 
regulate anxiety-like behavior at the level of the BLA, likely due to their role in neuronal circuits 
(Truitt et al., 2009). In the HPC and PFC, it has been demonstrated that CCK+BCs regulate the 
activity of P-cells through perisomatic inhibition (Freund & Katona, 2007; Whissell et al., 2015), 
however less functional data is available on their connectivity within the BLA (Duvarci & Pare, 
2014). It has been suggested that CCK+BCs in the BLA are analogous with cortical CCK+BCs, as 
both have relatively slow, adapting spiking patterns and are likely to respond to slow, asynchronous 
inputs (Bartos & Elgueta, 2012; Jasnow et al., 2009). However, there are multiple subtypes of 
CCK+INs across brain regions with different intrinsic properties (Jasnow et al., 2009). These 
differences are thought to be the result of specific ion channel variations (Jasnow et al., 2009).  
In multiple brain regions, CCK+INs have been found to express N-type calcium channels 
(CaV2.2) (Freund & Katona, 2007; Katona et al., 2001; McDonald & Mascagni, 2001; Szabo et al., 
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2014). CaV2.2 is a voltage-gated calcium channel (CaV) subtype critically involved in 
neurotransmitter release (Szabo et al., 2014). Located in the transmembrane domain, the ion 
channel-forming subunit of CaV2.2 (a1B) opens in response to membrane depolarization (Loane et 
al., 2007; Williams et al., 1992). Subsequently, calcium ions enter the neuron and interact with the 
SNARE protein complex to facilitate synaptic vesicle fusion and neurotransmitter exocytosis 
(Südhof, 2012). Functional studies have revealed that in the HPC, GABA release from CCK+IN 
is entirely dependent upon CaV2.2. However, the role of CaV2.2 role in regulating neurotransmitter 
release from CCK+INs has not been functionally described in the BLA. 
Currently, CaV2.2 is a target for treating neuropathic pain (Scott et al., 2002), but shows 
promise as a novel target for anxiety disorders (Newton & Messing, 2009). It has been proposed 
that the anxiolytic effects of Gabapentin (Lotarski et al., 2011) may be due to α2δ-dependent effects 
on CaV2.2 channels (Cassidy, Ferron, Kadurin, Pratt, & Dolphin, 2014; Zamponi, 2016), wherein 
neurotransmitter release is suppressed and excitatory synapses are downregulated throughout the 
brain (Eroglu et al., 2009). CaV2.2 antagonists have been found to be anxiogenic; administration 
of Zinconotide (Prialt) can produce anxiety and panic attacks (McCleskey et al., 1987; Scott et al., 
2002). While it has been shown CaV2.2 is implicated in anxiety-related neurotransmission, the 
underlying molecular mechanics are poorly understood and deserve further investigation. Here, I 
propose a comprehensive study combining transgenic mouse models, fluorescence microscopy, 
brain slice electrophysiology, and pharmacology to test the hypothesis that GABA release in 





All procedures were approved by the Institutional Animal Care and Use Committee at the 
University of New Hampshire (APPENDIX). To visualize the neuroanatomy of CCK+INs in the 
amygdala, we performed intersectional labeling using two molecular markers: CCK and Dlx5/6. 
CCK is expressed in both GABAergic and glutamatergic neurons, whereas Dlx5/6 is only 
expressed in GABAergic INs. We obtained a triple transgenic mouse line via the breeding 
schematic in Figure 9A. Initially, Cck-IRES-Cre mice (012706; The Jackson Laboratory) were 
crossed with Dlx5/6-Flpe mice (010815; The Jackson Laboratory). Cre and Flpe are recombinases 
expressed under the control of the CCK promoter and the Dlx5/6 promoter, respectively. Progeny 
from this initial cross, Cck-IRES-Cre; Dlx5/6-Flpe (abbreviated CCK-Dlx5/6), were dual 
transgenic mice with both alleles. Because the Dlx5/6 mutation could not be bread to homozygosity, 
we selected for CCK-Dlx5/6 mice that were homozygous for CCK-Cre and heterozygous for 
Dlx5/6-Flpe. To optimize the recombination efficiency, male CCK-Dlx5/6 mice were bred to 
female reporter mice (Ai65(RCFL-tdT)-D; 021875; The Jackson Laboratory) which contained the 
fluorescent protein tdTomato behind two recombinase target-flanked STOP cassettes. The first 
STOP cassette was flanked by loxP sites (recognized by Cre) and the second was flanked by FRT 
sites (recognized by Flpe). Progeny from this cross were triple-transgenic mice with the genotype 
Cck-IRES-Cre; Dlx5/6-Flpe; Ai65(RCFL-tdT)-D (abbreviated CCK-Dlx5/6-tdT). In these mice, 
Cre-Lox and Flpe-FRT recombination removed the two STOP cassettes, resulting in tdTomato 
fluorescence in tissues that expressed both CCK and Dlx5/6, i.e. GABAergic CCK+INs 
(abbreviated CCK+INs). Bright-red fluorescence is observable in the cell bodies and neuronal 
processes of CCK+INs throughout the BLA (Figure 10B). 
CCK is contained in glutamatergic cells in addition to GABAergic INs (Ma, Dankulich-
Nagrudny, & Lowe, 2013). This was evidenced when we bred dual-transgenic mice in which all 
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CCK+ cells/tissue were labeled. Cck-IRES-Cre mice were crossed with a Cre reporter mouse line 
(007914; The Jackson Laboratory) which contain the fluorescent protein tdTomato behind a single 
loxP-flanked STOP cassette (Ai14(RCL-tdT)-D). The resultant progeny, Cck-IRES-Cre; 
Ai14(RCL-tdT)-D (abbreviated CCK-tdT), show widespread, non-specific fluorescence in both 
glutamatergic and GABAergic CCK+ cells/tissue in the BLA (Figure 10A). 
To perform electrophysiological studies of CCK+IN/P-cell synapses, we used optogenetics. 
Optogenetics allow for the precise study of specific cell populations related to anxiety-like 
behavior (Tye & Deisseroth, 2012). The specific optogenetic tool we used was derived from 
channelrhodopsin (ChR), a cation-permeable channel that opens in response to a specific 
wavelength of light to cause membrane depolarization, action potentials, and neurotransmitter 
release (Britt, McDevitt, & Bonci, 2012; Lin, Knutsen, Muller, Kleinfeld, & Tsien, 2013). By 
embedding light-activatable cation channels in GABAergic CCK+ cells/tissue, we are able to 
selectively activate presynaptic GABA release from CCK+IN terminals. To accomplish this, we 
bred a second triple transgenic mouse line. 
CCK-Dlx5/6 mice were bred to a mouse strain that contains an allele that codes for red-
activatable channelrhodopsin (ReaChR) (Figure 9B). This mouse strain (R26 LSL FSF ReaChR-
mCitrine; 024846; The Jackson Laboratory) contained ReaChR and two STOP cassettes (loxP- 
and FRT-flanked). mCitrine, a yellow-fluorescent protein, was bound to the C-terminus of ReaChR, 
allowing for mapping of ReaChR expression. Progeny from this cross are triple-transgenic mice 
with the genotype Cck-IRES-Cre; Dlx5/6-Flpe; R26 LSL FSF ReaChR-mCitrine (abbreviated 
CCK-Dlx5/6-ReaChR). In these mice, Cre-loxP and Flpe-FRT recombination removed the two 
STOP cassettes, resulting in the expression of ReaChR in CCK+INs. This strategy allowed for 
stimulation of only GABAergic CCK+INs. To visualize channelrhodopsin expression both 
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glutamatergic and GABAergic CCK+ cells, Cck-IRES-Cre mice were crossed with mice that 
expressed a loxP-flanked STOP cassette and fluorescence-tagged (EYFP, yellow) 
Channelrhodopsin 2 (ChR2) cation channels (Ai32(RCL-ChR2(H134R)/EYFP); 024109; The 
Jackson Laboratory). Progeny from this cross were Cck-IRES-Cre; Ai32(RCL-
ChR2(H134R)/EYFP) mice (abbreviated CCK-ChR2) which displayed widespread EYFP 
fluorescence in the transmembrane domain of CCK+ cells/tissue. 
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Figure 9| Breeding schematics for triple-transgenic mouse models. Genotypes are depicted under each 
mouse; oval, promotor/marker; rectangle, recombinase; triangle, recombinase target; hexagon, STOP 
cassette. A| CCK-Dlx5/6-tdTomato breeding scheme. Top: Initial mating between Cck-IRES-Cre (black) 
and Dlx5/6-Flpe (white) mouse lines gave rise to CCK-Dlx5/6 progeny (brown). Middle: Second mating 
of CCK-Dlx5/6 mouse to Ai65(RCFL-tdT)-D mouse (grey) gave rise to CCK-Dlx5/6-tdT progeny (red). 
Combined action of Cre-loxP and Flpe-FRT recombination removed both STOP cassettes. Bottom: 
tdTomato is expressed in GABAergic CCK+ cells, represented in an intersectional breeding diagram. B| 
 35 
CCK-Dlx5/6-ReaChR breeding scheme. Top: Initial cross between Cck-IRES-Cre (black) and Dlx5/6-Flpe 
(white) mice produced CCK-Dlx5/6 offspring (brown). Middle: Second cross between CCK-Dlx5/6 and 
R26 LSL FSF ReaChR-mCitrine mice (ash) produced CCK-Dlx5/6-ReaChR progeny (yellow). Cre-loxP 
and Flpe-FRT recombination removed both STOP cassettes. Bottom: Red-activatable channelrhodopsin 
(ReaChR) was expressed in CCK+ GABAergic cells, represented in an intersectional breeding diagram.  
 
Genotyping 
To confirm the presence of alleles in a given mouse, we performed genotyping using tail 
biopsy. Tail biopsy was performed in P7-P9 pups. Genomic DNA was extracted using the Phire 
Animal Tissue Direct PCT kit (F140WH; ThermoFisher) according to manufacturer instructions. 
PCR was then performed with AmpliTaq Gold 360 (4398813; ThermoFisher) under the following 
conditions: a hot-start of 95oC for 10 min, followed by 35 cycles of 95oC for 30 sec, 60oC for 30 
sec, 72oC for 1 min, and a final step of 72oC for 7 min. Primer sequences and band size are located 
in Table 1. 
 
Mouse Line Primers Expected Products 
Cck-IRES-Cre F-MT: 5’-TGGTTTGTCCAAACTCATCAA 
F-WT: 5’-GGGAGGCAGATAGGATCACA 
R-CM: 5’-GAGGGGTCGTATGTGTGGTT 
Hom: 215 bp 
Het: 215 and 468 bp 







TG: 406 bp 
IC: 200 bp 
*PCR does not differentiate 









Het: 196 and 297 
WT: 297 





Hom: 284 bp 
Het: 284 bp and 297 bp 







Hom: 253 bp 
Het: 253 bp and 297 bp 
WT: 297 bp 
 
Table 1| Primer sequences and band sizes for mouse genotyping. Information on the primer sequences 
and expected PCR products for each mouse line used. F, forward primer sequence; R, reverse primer 
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sequence; MT, mutant; WT, wild-type; CM, common; Hom, homozygous; Het, heterozygous; TG, 
transgene; IC, internal control. 
 
Fluorescence Stainings 
Adult CCK-tdT and CCK-Dlx5/6-tdT mice (30 £ P < 120) were deeply anesthetized with 
isoflurane (07-893-1389; Patterson Veterinary). Proper levels of anesthesia were confirmed 
through the absence of a rear-foot reflex. Intraperitoneal injections (0.05 mL for females and 0.07 
mL for males) of Euthasol euthanasia solution (710101; Virbac Co.) were delivered to the lower-
right abdomen with a 26-gauge needle. Cardiac perfusions were performed using formalin solution 
(HT501128; Sigma-Aldrich) to attain brain fixation. Brains were rapidly dissected and stored at 
4°C in formalin solution for 24-72 hours for further fixation. 100 µm coronal brain slices were 
prepared using a vibratome (VT1000 S; Leica) and transferred to a 12-well plate (Greiner Bio-
One). Slices were washed for ten minutes three times in PBT (0.2% Triton X (T8787; Sigma-
Aldrich) in PBS (P3813; Sigma-Aldrich)) on an orbital rocker (SK-O180-S; Scilogex). To stain 
nucleic acids and identify cell bodies, slices were incubated for one hour at room temperature in a 
1:10000 dilution of SYTO-13 in PBT. SYTO-13 is a green fluorescent nucleic acid stain (S7575; 
ThermoFisher). Following incubation, slices were washed twice in PBT and once in PBS before 
mounting onto micro slides (48311-703; VWR) with Vectashield medium (H-1400; Vector 
Laboratories) and micro cover glass (48393-221; VWR). Slides were stored at 4°C for a minimum 
of 24 hours before confocal imaging. 
Fluorescence stainings for CCK-Dlx5/6-ReaChR mice followed the protocol described 
above, with a modification to the incubation step. CCK-Dlx5/6-ReaChR mice express the 
fluorophore mCitrine rather than tdTomato. mCitrine and SYTO-13 have partially overlapping 
emission spectra, so TO-PRO-3, another nucleic acid stain (T3605; Thermo-Fischer), was used 
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instead (1:4000 dilution). Fluorescence studies in CCK-ChR2 mice examined the native EYFP 
fluorophore, so sections were not incubated in a nucleic acid stain. Brains were sliced, washed, 
and mounted in the same manner as described above. 
 
Confocal Microscopy 
 Following fluorescence stainings, brain slices were imaged on one of two confocal systems. 
CCK-Dlx5/6-ReaChR sections were imaged on a Leica SP8 confocal using HyVolution super-
resolution imaging (Huygens Software). CCK-tdT, CCK-Dlx5/6-tdT, and CCK-ChR2 slices were 
imaged on a Zeiss LSM 510 Meta using accompanying LSM imaging software. A combination of 
argon and helium-neon lasers were used to excite fluorophores at 488 nm, 514 nm, 543 nm, and 
633 nm. For brain slices with multiple fluorescent proteins, multi-track acquisition was 
implemented to avoid excitation cross-talk. A series of band- and long-pass filters were applied to 
isolate emission peaks from individual fluorophores and prevent emission cross-talk. Fluorophores 
and their spectra were as follows (excitation/emission (nm)): SYTO-13 (488/509), EYFP 
(513/529), mCitrine (514/529), tdTomato (554/581), and TO-PRO-3 (642/661). Images were set 
to either a 1024 x 1024 or 2048 x 2048 frame size. A left-to-right scan with line averaging was 
used, each line being scanned eight times. The camera pinhole was kept at 1 airy unit across all 
imaging. The Zeiss range indication tool was used to adjust the amplifier offset and detector gain, 
preventing over/under saturation of signals. A combination of tile-scans, z-scans, and single-plane 
images of the BLA were taken at 5x, 10x, 20x, 40x, and 63x. Our primary objectives were to 
confirm the specificity to which our triple transgenic mouse models labelled CCK+INs and 
identify the neuroanatomy of CCK+INs in the BLA. 
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In Vitro Brain Slice Preparation  
No less than three adult male and three adult female CCK-Dlx5/6-ReaChR mice were 
deeply anaesthetized with isoflurane and decapitated. Brains were rapidly removed from the skull 
and placed into chilled and oxygenated artificial cerebral spinal fluid (‘cutting’ aCSF) containing 
(in mM): NaCl (130), KCl (3.5), KH2PO4 (1.1), MgCl2 (6), CaCl2 (1), dextrose (10), kynurenic 
acid (2), NaHCO3 (30), ascorbate (.4), thiourea (.8), and sodium pyruvate (2) at pH 7.35 and 310 
mOsm. 300 µm coronal slices containing the amygdala were prepared after mounting the brain in 
a vibratome. A scalpel was used to cut the corpus callosum and obtain hemi-coronal sections. 
Slices were transferred from the vibratome to a brain slice chamber (BSKH; Digitimer) containing 
oxygenated cutting aCSF and kept at 37°C for 15 minutes before transferring to a second slice 
chamber containing oxygenated room temperature ‘regular’ aCSF. Regular aCSF was composed 
of (in mM) NaCl (130), KCl (3.5), KH2PO4 (1.1), MgCl2 (1.3), CaCl2 (2.5), dextrose (10), NaHCO3 
(30), ascorbate (.4), thiourea (.8), and sodium pyruvate (2) at pH 7.35 and 300 mOsm. Slices were 
allowed to stabilize for one hour before transferring to the recording chamber where they remained 
for no more than two hours during patch-clamp recordings.  
 
Electrophysiology 
Our electrophysiology rig was housed on a nitrogen-fed workstation (Vision IsoStation; 
Newport). On the workstation was an upright microscope (BX51WI; Olympus) equipped with 
halogen (TH4-100; Olympus) and LED (Lumen 300; Prior Scientific) light sources. A CMOS 
microscopy camera (01-ROL-BOLT-M-12; QImaging) and 38mm c-mount (DC50NN; Qioptiq) 
were used in conjunction with capture software (Q-Capture Pro; QImaging) to perform differential 
interference contrast (DIC) microscopy. DIC microscopy was used to identify brain regions under 
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a 4x objective and P-cells under a 40x objective. The microscope was also equipped with an 
electrophysiology system consisting of a fixed-stage platform with manual x-y translator and a 
micromanipulator with a precision controller (1078-325-Y51; Sutter Instruments). Attached to the 
micromanipulator was a grounding electrode (E242; Warner Instruments) and headstage (CV-7B; 
Axon Instruments) connected to an amplifier (700B; Molecular Devices) and digitizer (1550A; 
Molecular Devices). Data from the digitizer was processed and recorded with the Axon pCLAMP 
10 software suite (Molecular Devices).  
Brain slices were held under the microscope in a rectangular slice chamber (RC-27LD; 
Warner Instruments) and anchored with a harp (64-0257; Warner Instruments). The slice chamber 
was housed in a magnetic platform (PM-7D; Warner Instruments) mounted to the microscope 
staging. Slices were kept healthy through a bath perfusion of ‘regular’ aCSF. aCSF was contained 
in a 60 mL syringe (BD Instruments) mounted above the microscope and oxygenated with 95 % 
O2/CO2. The perfusion was driven by a peristaltic pump (13-876; Fisher Scientific) which cycled 
regular aCSF from the 60 mL syringe to the slice chamber and back through laboratory-grade 
tubing (07407-71; Cole Palmer) and tubing connectors (64-1565; Warner Instruments). An IV flow 
regulator (ISGRF1001; Invacare Supply) was used to control the rate of the perfusion and a valve 
controller (VC-6; Warner Instruments) was used to start and stop aCSF flow.  
For patch-clamp electrophysiology experiments, borosilicate glass micropipettes with tip 
resistances between 4-7 mOhms were prepared using a micropipette puller (P-1000; Sutter 
Instruments) and filled with intracellular solution. Recordings involving action potentials and/or 
cellular firing properties utilized a potassium-based internal solution consisting of (in mM): K-
gluconate (140), HEPES (10), MgCl2 (3), K-ATP (2), Na2GTP (0.4), and phosphocreatine (5) at 
pH 7.4 and 290 mOsm. Recordings involving inhibitory postsynaptic currents (IPSCs) utilized a 
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cesium-based intracellular solution consisting of (in mM): Cs-gluconate (140), HEPES (10), 
MgCl2 (3), K-ATP (2), Na2GTP (0.4), and phosphocreatine (5) at pH 7.4 and 290 mOsm.  
Whole-cell patches were performed on P-cells in the BLA. P-cells were identified by their 
morphology and intrinsic firing properties (Figure 12A). P-cells characteristically display ‘non-
adapting’ firing patterns at a moderate frequency while CCK+INs display ‘adapting’ firing patterns 
at a much slower frequency (Freund & Katona, 2007; Rainnie et al., 1993). To evoke and 
characterize firing patterns, suspected P-cells were patched using the current-clamp technique and 
a supra-threshold square-pulse current was injected for three seconds as to elicit and action 
potential spike train. For IPSC recordings, P-cells were patched and held at 0 mV using the voltage-
clamp technique. LED flashes passed through a Texas Red filter, out of the 40x objective, and onto 
the slice, inducing IPSCs via optogenetic activation of ReaChR. As ReaChR expression is variable, 
LED intensity was adjusted for each cell to ensure baseline IPSCs had a peak amplitude large 
enough for pharmacologically-induced changes to be observed, but small enough to avoid 
exhausting or damaging tissue. IPSCs protocols were programmed in pCLAMP 10 software and 
consisted of stimulation and recording components. A single stimulation (0.1 ms LED application) 
occurred 10 ms into a 1000 ms recording window, also called a trace or sweep. Patches in which 
sweeps displayed polysynaptic input (multiple peaks) were discarded. Sweeps began every 10 or 
15 seconds depending on the individual P-cell’s ability to tolerate and recover from repeat 
stimulation and were continuously evoked for 45-60 minutes during pharmacology experiments.  
To confirm our recordings were strictly due to GABAergic activity, we performed two 
control experiments. A variable holding-potential protocol was used to determine if IPSCs 
displayed reversal potential and driving force properties characteristic of chloride. By altering the 
voltage-clamp, IPSCs were recorded at different P-cell membrane potentials. In 10 mV increments, 
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IPSCs were evoked at holding potentials of 20 mV through -90 mV for a total of twelve sweeps. 
After examining reversal potential and driving force, we performed a pharmacological test to 
confirm that our postsynaptic currents were produced through GABA binding to the GABAA 
receptor. P-cells were held at 0 mV and IPSCs were evoked for several minutes to establish a 
baseline peak amplitude. Bicuculline (BIC), a GABAA antagonist, was then added by pipette to 
the 60 mL syringe of aCSF. IPSCs were continually evoked until IPSC peak amplitude was 
eliminated. After the recording session was finished, the 60 mL syringe, tubing, ground electrode, 
40x objective, slice chamber, and harp were washed thoroughly with hydrogen peroxide and 
MilliQ water to avoid pre-exposing future tissue to residue from pharmacological agents. 
Following confirmation of GABAergic activity, we determined the sensitivity of IPSC peak 
amplitude to CaV2.2 block via ω-Conotoxin GVIA (CTX). In the same manner as with BIC, a 
baseline IPSC peak amplitude was established under control conditions. Afterwards, CTX was 
added to the bath perfusion and sweeps were continually evoked until no further changes in peak 
amplitude were observable. At this point, BIC was added to the bath perfusion to demonstrate that 
the brain slice was indeed being exposed to pharmacological agents.  
 
Pharmacology 
Drug dosing (working concentration) was determined by multiplying the EC50/IC50 of a 
given compound by twenty, ensuring full effects would be observable in-perfusion. Stock 
concentrations were made at 1000x working concentrations and stored at -20°C. BIC (ab120107; 
Abcam) and CGP (ab120167; Abcam), GABAA and GABAB antagonists, respectively, were added 
to the bath perfusion (100 µM and 2 µM, respectively) to confirm that IPSCs were due to GABAA 
receptor activity. CTX (ab120215; Abcam), a specific CaV2.2 antagonist, was added to the bath 
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perfusion (1 µM) to study the role CaV2.2 in GABA release from CCK+INs onto P-cells in the 
BLA. Of note, we later determined that 1 µM CTX was a much higher dose than required. 
Equivalent effects were observable using 300 nM, and we used this dose in future experiments 
(CHAPTERS 2/3). Smaller lipophilic compounds took considerably less time to display full 
effects on peak amplitude compared to larger lipophobic compounds. BIC permeated the slice and 
blocked IPSCs typically within five minutes, whereas CTX typically took fifteen minutes.  
 
Data Analysis  
After electrophysiology experiments were recorded, IPSC data was analyzed in Clampfit 
software and plotted in Origin 6.1 (OriginLab). Sweeps were selected to represent the changes that 
occurred to IPSCs under various holding voltages and pharmacological conditions. For 
pharmacological studies, we used IPSC peak amplitude (in pA) as a quantitative measure of the 
amount of GABA released from CCK+INs onto P-cells. Peak amplitudes were calculated by 
subtracting baseline sweep current (pre-IPSC) from the maximum positive-going current of the 
sweep, which occurred just milliseconds after LED stimulation. The time at which each sweep 
began was converted into minutes, to create a timescale. For recordings in which sweeps occurred 
in 15 second intervals, sweep 1 = 0 min, sweep 2 = 0.25 min, sweep 3 = 0.5 min, etc. The peak 
amplitude and time values for each sweep were plotted in Origin 6.1. A time-course line plot was 
created from this data for each cellular recording (n = 7). IPSC peak amplitude (pA) was assigned 
to the y-axis and time (min) to the x-axis. 
A two-point segment graph was created to compare mean IPSC peak amplitude under 
control and CTX conditions across multiple cells (Figure 13 - bottom right). Recordings from 
male and female CCK-Dlx5/6-ReaChR mice were pooled in this plot, as there was no significant 
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association between sex and CTX effects (see details in results). The mean control conditions IPSC 
peak amplitude was calculated by averaging peak amplitude values from sweeps prior to CTX 
addition to the bath perfusion. CTX-dependent effects were examined only after the point in the 
time-course plot at which peak amplitude no longer decreased, i.e. the ‘plateau’ phase. From this 
time point forward, peak amplitudes across sweeps were averaged to obtain the mean peak 
amplitude under CTX conditions. For within-animal analysis, a one-tailed paired t-Test was 
performed in Microsoft Excel 2016 to determine if there was a significance to the changes in peak 
amplitude when moving from control to CTX conditions. For cross-animal analysis, control and 
CTX condition peak amplitudes were averaged for the seven recordings and plotted as grey circles 
in the two-point segment plot. The standard deviation (SD) and standard error of the mean (SEM) 
were calculated for both conditions as both numerical values (in pA) and percentages. Vertical 
black bars attached to the gray average peak amplitude circles on the two-point segment plot 
represent the SEM (in pA). 
 
Results 
Histological Characterization in CCK-tdT and CCK-Dlx5/6-tdT Mice  
 Fluorescence experiments in CCK-tdT mice labelled CCK+ cell/tissues with tdTomato and 
cell bodies with SYTO-13 (Figure 10A). Confocal microscopy images display widespread CCK 
expression with notable regions of concentrated signal. CCK fluorescence is particularly intense 
in the BLA, layer 2 of the piriform area, the piriform-amygdalar area, and the endopiriform nucleus 
(Figure 10A - left). CCK expression is weak in the CeA and layer 1 of the piriform area. Like 
CCK, SYTO-13 signaling is also low in the thalamus and layer 1 of the piriform area, as well as 
the external capsule (Figure 10A - middle). Colocalization of CCK and SYTO-13 signal, 
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represented by yellow fluorescence, indicates a CCK+ cell (Figure 10A - right). Groups of CCK+ 
cells appear in the medial portion of the BLA, the LA, and the dorsal endopiriform nucleus.  
Fluorescence experiments in CCK-Dlx5/6-tdT mice labelled CCK+INs with tdTomato and 
cell bodies with SYTO-13 (Figure 10B). Confocal images show that tdTomato expression is 
restricted to a fewer number of cells than in the CCK-tdT mouse. CCK+ signaling is constrained 
to GABAergic INs and their projections. Cell bodies strongly express tdTomato while expression 
in what appear to be neuronal projections is much milder and variable. Based on morphology, 
thicker projections (i.e. primary dendrites) can contain more CCK expression and higher levels of 
fluorescence than thinner projections (i.e. secondary/tertiary dendrites). Thin, faint networks of 
CCK+ projections can be seen in the center of the BLA. CCK+INs are mostly absent in the external 
and amygdalar capsules but are prevalent in the ventral/dorsal endopiriform nucleus and the BLA 
(Figure 10B - left). SYTO-13 signaling appears prevalent and uniform in the BLA, absent in the 
external/amygdalar capsules, and sparse in the ventral endopiriform nucleus (Figure 10B - middle). 
Since CCK-Dlx5/6-tdT mice possess the Dlx5/6 promotor, colocalization of CCK and SYTO-13 
signal is indicative of GABAergic CCK+INs (Figure 10B - right). Compared to the CCK-tdT 
mouse (Figure 10A - right), there is very little colocalization signal in the CCK-Dlx5/6-tdT model. 
Colocalization distribution appears more uniform however, and the clustering of highly 
concentrated yellow signal in Figure 10A - left is not present. Web-like tdTomato signaling 
(Figure 10B - left) surrounds cell bodies (Figure 10B - right), a characteristic pattern of 
perisomatic inhibitory networks.  
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Figure 10| CCK expression in CCK-tdT mice and GABAergic CCK expression in CCK-Dlx5/6-tdT 
mice. A| Fluorescence images of coronal brain slices containing the BLA from an adult CCK-tdT mouse 
(10x magnification). Left: tdTomato (red) is expressed in all CCK+ cells/tissue. Middle: SYTO-13 nucleic 
acid stain (green) labels cell bodies. Right: In an overlay of the two channels, cell bodies that express CCK 
appear yellow due to colocalization of SYTO-13 and tdTomato signal. B| Fluorescence images of coronal 
brain slices containing the BLA from an adult CCK-Dlx5/6-tdT mouse (20x magnification). Left: 
Cells/tissue that contain both CCK+ and Dlx5/6 promoters express tdTomato. Middle: Cells bodies are 
stained with SYTO-13. Right: In an overlay of the two channels, CCK+INs appear yellow due to 
colocalization of tdTomato and SYTO-13 signal.  
 
Characterization of Fluorescence in CCK-ChR2 and CCK-Dlx5/6-ReaChR Mice 
CCK-ChR2 mice express EYFP-tagged ChR2 in CCK+ cells/tissue (Figure 11A). The 
BLA, CeA, and cortical tissue display weak EYFP signaling while the piriform area and the 
endopiriform nucleus display stronger signaling (Figure 11A - left). At 40x magnification, ChR2 
expression is absent in what appear to be cell bodies and blood vessels (Figure 11A - right). 
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Overall fluorescence levels are moderate, but strong EYFP signaling in what morphologically 
appear to be neuronal projections can be distinguished from the background in the lower right-
hand side of Figure 11A - right. Focusing on the small bulbous structures containing strong EYFP 
signal throughout the tissue, it looks as if ChR2 is expressed in CCK+ synaptic terminals.  
CCK-Dlx5/6-ReaChR mice express mCitrine-tagged ReaChR in CCK+INs. Confocal 
images of fluorescence in these mice contain strikingly specific and distinguishable mCitrine 
expression (Figure 11B - left). Since ReaChR expression is confined to GABAergic CCK+INs, 
cell and their projections are far easier to distinguish from the background than in Figure 11A - 
right. ReaChR is embedded in the transmembrane domain and fluorescence is restricted to the C-
terminus of these cation channels, thus mCitrine signal is not as robust as tdTomato signal under 
the microscopy conditions that we used for imaging. Based on morphology, the thin, rod-like 
projections with high fluorescence could represent ReaChR in CCK+IN dendrites while the small, 
bulbous areas of high fluorescence could represent ReaChR in CCK+IN synaptic terminals 
(Figure 11B - right). Some CCK-negative cells, represented by empty/black circles, appear to be 
isolated from CCK+IN innervation in the lower right-hand side of Figure 11B - left. Other CCK-
negative cells are surrounded by mCitrine fluorescence in what appear to be patterns of perisomatic 
inhibition by CCK+INs (Figure 11B - left). A CCK+IN with extensive ReaChR expression is 
observable in Figure 11B - right along with its highly-fluorescent projections. 
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Figure 11| Channelrhodopsin expression in the BLA of CCK-ChR2 and CCK-Dlx5/6-ReaChR mice. 
A| Confocal images of 
fluorescence in coronal brain 
slices containing the BLA 
from an adult CCK-ChR2 
mouse. EYFP (yellow) is 
bound to the C-terminus of 
channelrhodopsin-2 and 
expressed in CCK+ 
cells/tissue. Left: Widespread 
EYFP expression can be seen 
in and around the BLA. Right: 
EYFP can be seen in what 
appear to be dendrites and 
synaptic terminals, but not in 
cell bodies. B| Confocal 
images of fluorescence in 
coronal brain slices containing 
the BLA from an adult CCK-
Dlx5/6-ReaChR mouse. 
mCitrine (yellow) is bound to 
the C-terminus of Red-
activatable channelrhodopsin 
(ReaChR) and expressed in 
GABAergic CCK+INs. Left: 
Non-fluorescent cell bodies 
are heavily innervated by 
ReaChR-mCitrine, indicating 
postsynaptic currents can be 
recorded from these cells using 
optogenetics. Right: ReaChR 
can be seen in a CCK+IN and 
its projections. Some surrounding cells are innervated by the CCK+IN in patterns characteristic of 
perisomatic inhibition, while others receive no innervation. 
 
Light-evoked IPSCs in CCK+IN/P-cell Synapses in the BLA 
The BLA (Figure 12A - left) contains P-cells with piriform morphology and projections 
on their apical and basal ends (red circle in Figure 12A - middle). P-cell displayed non-adapting 
firing patterns when stimulated by a supra-threshold square-pulse current injection (Figure 12A - 
right). When P-cells were held at 0 mV, a positive-going inhibitory postsynaptic current (IPSC) 
was produced (black trace in Figure 12B - left). The driving force for Cl- was strong and inwards 
when the membrane potential was clamped at 0 mV (the equilibrium potential for chloride is -70 
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mV). When P-cells were held at -70 mV, there was no IPSC following optogenetic stimulation, as 
there was no driving force for Cl- at this membrane potential (mint trace in Figure 12B - left). 
When P-cells were held at -90 mV, a negative-going reverse IPSC was produced (purple trace in 
Figure 12B - left). At this membrane potential, the driving force for Cl- was small and outwards, 
into the extracellular space. Exposing P-cells to BIC lead to an elimination of control-condition 
IPSCs (Figure 12B - middle). BIC swiftly, totally, and irreversibly blocked optogenetically-
evoked IPSCs in CCK+IN/P-cell synapses in the BLA of CCK-Dlx5/6-ReaChR mice (Figure 12B 
- right).  
 
Figure 12| Morphophysiology and postsynaptic currents in CCK+IN/P-cell synapses in the BLA. 
Scale bars represent size in DIC images and time/current in IPSC traces. A| Identifying P-cells in the BLA 
of adult CCK-Dlx5/6-ReaChR mice. Left: DIC microscopy of the BLA contained in the brain slice chamber 
(4x magnification). Middle: Micropipette performing a whole-cell patch on a P-cell in the BLA (red circle). 
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Distinct piriform morphology and projections are observable. Right: A non-adapting firing pattern 
characteristic of P-cell intrinsic firing properties was produced by a supra-threshold square-pulse current 
injection. B| Confirming GABAergic activity of IPSC in CCK+IN/P-cell synapses. Left: IPSCs evoked at 
variable holding potentials display patterns representative of the driving force of Cl-. A positive-going peak 
is produced when the P-cell is held at 0 mV (top, black). No peak is produced at -70 mV (middle, mint), 
and a negative-going peak is produced at -90 mV (bottom, purple). Middle: IPSC traces under control and 
bicuculline (BIC) conditions. BIC (100 µM) eliminates IPSCs. Right: Time-course plot of IPSC peak 
amplitude under control and BIC conditions (indicated in the color-coded timeline). BIC added to the bath 
perfusion after 3 min rapidly eliminates IPSCs. Peaks are initially 400 pA and reduce to <10 pA after 8 min. 
There is no IPSC recovery upon continued stimulation.  
 
Cav2.2 Block Reduced IPSC Peak Amplitude in CCK+IN/P-Cell Synapses in the BLA 
CTX reduced IPSC peak amplitude in CCK+IN/P-cell synapses in the BLA of CCK-
Dlx5/6-ReaChR mice (Figure 13 - top right). A cellular recording is represented in a time-course 
plot wherein average IPSC peak amplitude drops from 230 pA to 66 pA following CTX conditions 
(Figure 13 - left). It took about fifteen minutes for CTX to decrease peak amplitude to a new stable 
baseline, and five additional minutes for BIC to eliminate the remaining IPSCs (Figure 13 - left). 
These two drugs have different pharmacokinetics and pharmacodynamics, thus permeate the slice 
and act upon their targets at different rates. A total of seven cells were treated with CTX and their 
average peak amplitudes under control and CTX conditions are represented in a two-point segment 
plot (Figure 13 - bottom right). Each pair of circles represents the average IPSC peak amplitude 
before and after CTX treatment for one cellular recording. Comparisons across cells were made 
by calculating the percentage change in IPSC peak amplitude for each recording. The mean IPSC 
peak amplitude decrease for all seven cells was 51% (SD = 14%, SEM= 7%), with an average 
amplitude of 211 pA (SD = 103 pA, SEM = 39 pA) under control conditions and 97 pA (SD = 40 
pA, SEM = 15 pA) under CTX conditions. There was no association between sex and CTX effects 
(51.87% mean peak amplitude decrease for males vs. 49.56% for females). A one-tailed paired t-
Test on average control and CTX peak amplitudes produces a p-value of 0.0046. We conclude that 
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there was a significant effect of CTX on IPSC peak amplitude, and that GABA release from 
CCK+INs in the BLA is partially CaV2.2-dependent. 
 
Figure 13| CaV2.2 antagonism reduces IPSC peak amplitude in CCK+IN/P-cell synapses in the BLA. 
Optogenetically-evoked IPSC were recorded in adult CCK-Dlx5/6-ReaChR brain slices. Left: Time-course 
plot of IPSC peak amplitude under three pharmacological conditions (indicated in color-coded timeline). 
w-Conotoxin GVIA (CTX, 1 µM) and bicuculline (BIC, 100 µM) were added to the bath perfusion at 30 
and 49 min, respectively. Peak amplitude was initially 230 pA but reduced to 66 pA following CTX addition. 
Blockade stabilized at 41 mins. BIC addition eliminated remaining IPSCs. Top right: Representative IPSCs 
traces from each of the three pharmacological conditions. The top IPSC (black) is a control trace. The 
middle (red) and bottom (blue) IPSCs are traces under CTX and BIC conditions, respectively. Scale bars 
represent time and current values. Bottom right: Two-point segment plot of average IPSC peak amplitude 
under control and CTX conditions for multiple recordings. Each pair of circles represents one cell (n = 7). 
CTX significantly decreased peak amplitude (p = 0.0046, one-tailed paired t-Test) by an average of 51% 
compared to control conditions (SD = 14%, SEM = 5%). Grey circles represent the mean IPSC peak under 





Connections between CCK+INs and P-cells have been described in the cerebral cortex 
(Freund, 2003), hippocampus (Whissell et al., 2015), and amygdala (Andrási et al., 2017; Freund 
& Katona, 2007). Additionally, the role of CaV2.2 in CCK+IN/P-cell synapses has been described 
for the hippocampus (Szabo et al., 2014). This is the first study to demonstrate the role of CaV2.2 
in CCK+IN/P-cell synapses in the BLA. GABA release from CCK+INs onto P-cells in the CA3 
region of the hippocampus was shown to be entirely blocked by CTX (Szabo et al., 2014). We 
found that in the BLA, GABA release is only partially blocked (51%). Our findings suggest that 
CCK+IN/P-cell are functionally distinct in the BLA and the hippocampus. 
 
Specificity of CCK-Dlx5/6-ReaChR Mouse Model 
Optogenetics allows for a level of precision in circuit-level research unattainable with 
traditional methods like electrical stimulation (Tye & Deisseroth, 2012). Electrical stimulation is 
a longstanding means of inducing neurotransmitter release and studying neurophysiology. While 
there are many appropriate applications of electrical stimulation, it is impractical to try to isolate 
specific cell circuitry using this technique. Investigations are limited because electrical stimulation 
excites all of the cells in proximity of the microelectrode. Accordingly, postsynaptic currents are 
the result of cumulative neurotransmitter release from multiple inputs, some of which may not be 
the target of study. Optogenetic stimulation induces transmitter release by opening light-gated ion 
channels and depolarizing the membrane of a genetically targeted neuronal population, thus the 
power of optogenetics lies in its cell specificity.  
Critical to our research interests, genetic targeting of GABAergic INs has been made 
possible in recent years. Taniguchi and colleagues (2011) used Cck-IRES-Cre, Dlx5/6-Flp, and dual 
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recombinase-expressing mice to label GABAergic CCK+INs with GFP. Our CCK-Dlx5/6-tdT 
mouse model followed similar intersectional breeding framework, and as a result we are confident 
in our specific labelling of CCK+INs with tdTomato. Also critical to our research interests, 
optogenetic techniques have successfully been used to study perisomatic inhibitory circuits in the 
amygdala. Andrási and colleagues (2017) present electrophysiological data demonstrating potent 
inhibition of P-cells by local CCK+INs, as well as ChR2-mediated excitation of P-cells. 
Accordingly, our CCK-Dlx5/6-ReaChR mouse model aligns with prior models and can be used to 
make conclusions regarding CCK+IN/P-cell neurophysiology in the BLA.  
 
Expression of tdTomato and ChR in CCK+ Cells in the BLA  
Confocal microscopy images of fluorescence in CCK-tdT mice demonstrate widespread 
tdTomato expression throughout the brain slice (Figure 10A - left). This is to be expected, as the 
amygdala and surrounding cortical regions are known to contain high levels of CCK, both as a 
marker for excitatory and inhibitory cells (Beinfeld, Meyer, Eskay, Jensen, & Brownstein, 1981). 
Accordingly, the widespread expression of ChR2 in CCK+ cells from CCK-ChR2 mice is also to 
be expected (Figure 11A). We observe similar patterns of tdTomato and EYFP fluorescence in 
CCK+ cells (Figure 10A/11A - left). Of note, the structures with intense fluorescence are related 
to the limbic system. Fluorescence is particularly concentrated in the LA and medial BLA, as well 
as the cortical piriform area, the piriform-amygdalar area, and the endopiriform nucleus. The latter 
three brain areas are part of the piriform cortex, a structure which is thought to be implicated in 
olfactory-based learning (Krettek & Price, 1977; Majak, Pikkarainen, Kemppainen, Jolkkonen, & 
Pitkänen, 2002). High expression of CCK+ cells has been reported in the piriform-amygdalar area 
and the endopiriform nucleus previously (Ingram, Krause, Baldino, Skeen, & Lewis, 1989). The 
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role of CCK in olfactory structures has been identified (Ma et al., 2013), and it continues to be a 
neurotransmitter of interest for sensory-limbic integration. Therefore, our observations of CCK 
expression and tdTomato/EYFP fluorescence in CCK-tdT and CCK-ChR2 mice support previous 
findings.  
Fluorescence experiments in CCK-Dlx5/6-tdT mice illustrate that CCK expression is far 
more refined when restricted to GABAergic IN populations (Figure 10B - left vs Figure 10A - 
left). Additionally, there are far fewer light-gated ion channel expressed in CCK-Dlx5/6-ReaChR 
mice (Figure 11B - right) when compared to CCK-ChR2 mice (Figure 11A - right). By 
incorporating Dlx5/6-Flpe into our CCK-Dlx5/6-tdT and CCK-Dlx5/6-ReaChR triple transgenic 
mouse models, tdTomato/mCitrine fluorescence is only expressed in GABAergic CCK+INs 
(Taniguchi et al., 2011). As described by Freund (2007), CCK+IN innervation exerts heavy control 
over P-cells the BLA. This innervation appears to be isolated in both triple transgenic mouse 
models and visualized in Figure 10B - left and Figure 11B - right. CCK+INs sit atop web-like 
patterns of low-level tdTomato fluorescence (Figure 10B - left) and mCitrine fluorescence 
encircles empty cell bodies (Figure 11B - right). Both patterns likely indicate perisomatic 
inhibitory connections with local P-cells. Strikingly similar images are presented by Rovira-
Esteban and colleagues (2017), who selectively targeted GABAergic CCK+INs using a BAC-
CCK-DsRed mouse line (adapted from Máté et al., 2013). These patterns are not observable in 
CCK-tdT mice (Figure 10A) or CCK-ChR2 mice (Figure 11A), as glutamatergic and GABAergic 
CCK+ expression are homogenized in these lines. 
 
GABA Release from CCK+INs onto P-cells in the BLA is Partially CaV2.2-dependent 
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When analyzing neurotransmitter release, IPSCs are a useful quantitative measurement as 
they allow for direct insight into fast-synaptic activity. The amplitude of an IPSC is reflective of 
the degree of inward anion (Cl-) flow, which is the product of GABA binding to GABA receptors. 
Greater amounts of neurotransmitter binding will produce stronger IPSCs with higher peak 
amplitudes. Reduced neurotransmitter binding will produce weaker IPSCs with lower peak 
amplitudes. 
We observe decreases in IPSC peak amplitude following CTX addition in all patch-clamp 
recordings (Figure 13 - bottom right). This consistency suggests that CaV2.2-dependent GABA 
release from CCK+INs is pervasive and present to some degree around most P-cells in the BLA. 
While pervasive, it does not appear uniform. Neither total IPSC block nor zero IPSC block was 
observed in any of our recordings; decreases in peak amplitude ranged from 32% to 71%. There 
is likely variation in the degree to which CaV2.2 is expressed in presynaptic CCK+IN terminals. 
The remaining peak amplitude suggests that there are additional CaV2 subtypes which mediating 
neurotransmitter release. P/Q-type channels facilitate GABA release from PV+INs onto P-cells, 
and CCK+INs are closely paired with PV+INs in perisomatic inhibitory circuits (Sparta et al., 
2014; Zamponi & Currie, 2013). Accordingly, P/Q-type channels may also play a role in 
transmitter release from CCK+IN terminals in the BLA. It has been demonstrated previously that 
there is a degree of functional compensation between P/Q-type channels and N-type channels in 
the presynaptic terminal (Inchauspe, 2004). Another possible CaV2 subtype, the R-type calcium 
channel, has been shown to partially contribute to action potentiation in presynaptic P-cell inputs 
(Wu, Borst, & Sakmann, 1998). R-type blockers (i.e. Lamictal) are used as mood-stabilizing drugs 
and in the treatment of affective disorders (Zamponi, 2016), thus may have some role in anxiety-
related neuronal output from the BLA. As the functional roles of many presynaptic calcium 
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channels in regulating neurotransmitter release across brain regions remain unidentified, further 
pharmacological testing is required to determine which CaV subtypes regulate GABA release in 
CCK+IN/P-cell synapses in the BLA.  
Observations of partial CaV2.2-dependency in CCK+IN/P-cell synapses suggest that 
CaV2.2 differentially regulates neurotransmitter release in the BLA compared to other brain 
regions. Szabó and colleagues (2014) report complete IPSC blockade in response to CTX (i.e. total 
CaV2.2-dependency) in CCK+IN/P-cell synapses in the hippocampus (CA3). Partial reduction of 
IPSC peak amplitude in the BLA is not likely due to of insufficient CTX dosing. Szabó and 
colleagues (2014) saw complete block with a 50 nM dose while we used 1 µM. Moreover, we 
incrementally increased CTX concentration after decreases in IPSC peak amplitude had plateaued 
and no further effects were observable (Figure 13 - left).  
 Overall, our findings are an important contribution to the growing understanding of the 
molecular mechanisms involved in anxiety. We demonstrate that although CCK+IN/P-cell 
synapses are also found in the HPC and PFC, these circuits are differentially regulated by CaV2.2 
in the BLA. Additionally, our results challenge the notion that CaV2.2 is the only CaV2 subtype 
involved in regulating neurotransmitter release from CCK+INs. These two concepts are important 
when considering the conflicting anxiogenic and anxiolytic properties reportedly caused by CaV2.2 
antagonists. Anxiety-related neuronal activity and ultimately the experience of anxiety-like 
symptoms are likely differentially modulated by CaV2.2 in different brain regions. As a result, 
novel CaV2.2-based pharmacological treatments for anxiety disorders should consider region-
specific effects and target precise anxiogenic circuits.  
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Additional Considerations for Future Research 
 CaV2.2 blockade partially reduced IPSC peak amplitude in CCK+IN/P-cell synapses in the 
BLA. By blocking additional CaVs, we may be able to determine which additional subtypes are 
behind the remaining peak amplitude. Following a similar electrophysiology protocol, additional 
CaV antagonists could be added to the bath perfusion following ω-Conotoxin GVIA. There are 
pharmacological agents that specifically target other CaV subtypes; Nimodipine is an L-type 
blocker, ω-Agatoxin IVA is a P/Q-type blocker, and SNX 482 is an R-type blocker. By blocking 
CaV subtypes in succession, we can fully eliminate IPSCs. If this process of multiple drug 
conditions prolongs recordings to the point at which they become detrimental to slice health, 
multichannel blockers could be used instead. Drugs like cilnidipine (N- and L-type blocker) or ω-
Conotoxin MVIIC (N- and P/Q-type blocker) may eliminate IPSCs in our system. 
The CCK-Dlx5/6-ReaChR mouse model we have developed has incredible potential for 
studying CCK+INs. These studies do not have to be limited to circuits in the BLA, or even to 
electrophysiology experiments. ReaChR has been shown to enable transcranial optogenetic 
activation of neurons in deep brain structures (Lin et al., 2013). Therefore, the role of CCK+INs 
in behavior could be examined. Local injections, toxins, and other genetic manipulations would 
allow us to target the underlying components behind CCK+IN-related behaviors. Fluorescence 
experiments in our CCK-Dlx5/6-tdT mouse line have shown extensive CCK+IN expression 
throughout the brain and spinal cord. There are major CCK+IN-mediated properties left 
unexplored at the behavioral and cellular level. For example, CCK+INs have been shown to 
innervate other CCK+INs, parvalbumin-expressing basket cells (PV+BCs), and even themselves 
via autapses (Freund, 2003; Fukudome et al., 2004; Rainnie et al., 1993). We have demonstrated 
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that we can distinguish between P-cells and INs in patch-clamp recordings; additional research 
could study the role of CaV2.2 in CCK+IN/CCK+IN synapses.  
In addition to CCK+INs, PV+INs synapse onto the soma of P-cells to form a system of 
perisomatic inhibition. This type of inhibition has been well studied in the hippocampus and 
cerebral cortex (Freund, 2003), however less is known about its role in the BLA. PV+INs have 
firing properties distinct from CCK+INs, indicating they process inputs differently. PV+INs fire 
fast non-adapting spiking patterns, allowing them to process multiple converging stimuli (Bartos 
& Elgueta, 2012). Despite the relevance of spiking frequencies on PV+IN function, the ion channel 
composition underlying these distinctive properties has not been fully described in the BLA. 
Spiking frequency depends on the concerted activity of various ion channels, including CaVs and 
calcium-activated potassium channels (KCas). Generally, CaVs provide calcium for the activation 
of KCas; a form of selective coupling that then hyperpolarizes neurons and reduces spiking 
frequency (Womack, 2004). In the future, we can propose a comprehensive study that combines 
in vitro electrophysiology, transgenic mouse models, and pharmacology to compare CaVs and KCas 
in CCK+INs and PV+INs in the BLA, to determine which channels underlie higher spiking 




CHAPTER 2: CB1-MEDIATED MODULATION OF GABA RELEASE FROM CCK+ 
INTERNEURONS ONTO PYRAMIDAL CELLS IN THE BASOLATERAL AMYGDALA 
 
Abstract 
The endocannabinoid (eCB) system is a network of receptors and ligands throughout the 
mammalian brain implicated in anxiety. The type-1 cannabinoid receptor (CB1) is expressed at 
high levels in the basolateral amygdala (BLA), a brain region involved in regulating anxiety-like 
behaviors. The BLA is the main source of excitatory neuronal output from the amygdala to brain 
regions like the prefrontal cortex and hippocampus. This output is facilitated by pyramidal cells 
(P-cells) and regulated by local inhibitory interneurons (INs). INs that express the neuropeptide 
cholecystokinin (CCK+) are known to co-express CB1. CB1 regulates neurotransmitter release 
from CCK+INs by downregulating voltage-gated calcium channels (CaVs) in the presynaptic 
terminal. P-cells disinhibition in the BLA may contribute to increased anxiety-like behaviors. CB1-
mediated inhibition can occur in a ligand-dependent (phasic) and ligand-independent (tonic) 
manner. It has been demonstrated that CB1 is expressed in CCK+INs in the BLA, however the 
underlying molecular mechanisms of these channels is not well understood. Using a combination 
of transgenic mouse models, immunofluorescence, electrophysiology, and pharmacology, we 
aimed to determine if/how CB1 modulates CCK+IN/P-cell synapses in the BLA. Our confocal 
microscopy experiments revealed heavy colocalization of CB1 and CCK+IN signal in both the 
BLA and hippocampus. Using optogenetic stimulation and whole-cell patch clamp 
electrophysiology in our transgenic mouse model (CCK-Dlx5/6-ReaChR), we evoked GABA 
release from CCK+INs and recorded inhibitory postsynaptic currents (IPSCs) in P-cells. We then 
determined how sensitive GABA release was to CB1 modulation by observing IPSC peak 
amplitude under control condition and following bath addition of a CB1-agonist (2-AG) and a CB1-
antagonist (AM251). Our initial recordings suggests there is both phasic and tonic CB1-mediated 
inhibition of GABA release from CCK+INs in the BLA. IPSC peak amplitude decreased by 26% 
from control to 2-AG conditions and increased by 34% from control to AM251 conditions. 
Following the publication of a comprehensive study on CCK/CB1-expressing INs in the BLA by 
Rovira-Esteban and colleagues (2017), we decided to discontinue electrophysiology recordings 
and reallocate our mice to focus on novel experiments. Our preliminary data serves to confirm the 
findings presented by Rovira-Esteban and colleagues (2017), and our model transgenic mouse 
model serves as a tool for future studies on the molecular components underlying CB1-mediated 
inhibition in the BLA. 
 
Introduction 
The endocannabinoid (eCB) system is a series of ligands and receptors integral for 
regulating synaptic transmission in brain areas like the prefrontal cortex (PFC), hippocampus 
(HPC), and basolateral amygdala (BLA). Circuit-level modulation of the eCB system can have 
large impacts on emotion and behavior, particularly in areas involved in anxiety (Lutz et al., 2015). 
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In the brain regions implicated in anxiety, type-1 cannabinoid receptors (CB1) are located in 
presynaptic terminals. CB1 is activated by the eCBs 2-Arachidonoylglycerol (2-AG) and 
anandamide (AEA), as well as exogenous cannabinoids (CBs) like tetrahydrocannabinol (THC) 
and cannabidiol (CBD) (Katona et al., 2001; Lee et al., 2015). Upon eCB/CB binding, CB1 
downregulates voltage-gated calcium channels (CaVs), preventing calcium entry, vesicular fusion, 
and neurotransmitter release (Guo & Ikeda, 2004). CB1 is believed to target and couple with CaV2 
channels, as they are also transmembrane proteins located in the presynaptic terminal (Alger, 2002; 
Wilson et al., 2001). CB1 and CaV2 are present in the excitatory cortical inputs to the amygdala 
(via the external capsule), and in inhibitory inputs from local INs (Azad, 2003). Dual expression 
in excitatory and inhibitory inputs suggests that eCBs can modulate output from the BLA and 
subsequently anxiety-related behaviors (Katona et al., 2001; Patel, Kingsley, MacKie, Marnett, & 
Winder, 2009; Yoshida et al., 2011). Additionally, it has been proposed that by acting with the eCB 
system, cholecystokinin-containing (CCK+) interneurons (INs) modulate fear inhibition and 
extinction (Bowers et al., 2012). 
CB1 is selectively expressed in CCK+INs over other IN subtypes in the hippocampus 
(Katona et al., 2001). CCK+INs are known to regulate glutamatergic signaling of local pyramidal 
cells (P-cells), and are found in the neuronal output circuits of brain areas like the BLA, ventral 
HPC, and medial PFC (Freund & Katona, 2007). CCK+IN synapses can undergo CB1-mediated 
depolarization-induced suppression of inhibition (DSI), a form of phasic, short-term inhibition 
(Zhu, 2005), as well as eCB-mediated long-term depression (LTD), a form of tonic, CB1-
independent inhibition (Marsicano et al., 2002). Both DSI and LTD are necessary for fear 
extinction (Chhatwal et al., 2009), a behavioral response facilitated by reciprocal connections from 
the infralimic cortex (IL) of the medial PFC to the BLA (Sierra-Mercado et al., 2011). In the BLA, 
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CB1 expression is found in the CCK+INs involved in perisomatic inhibition (basket cells (BCs)) 
(Mascagni & McDonald, 2003). These CCK+INs can be further grouped according to their level 
of CB1 expression; so-called ‘high CB1-expressing’ CCK+INs are sparsely distributed while ‘low 
CB1-expressing’ CCK+INs are more evenly-distributed (Marsicano & Lutz, 1999; Yoshida et al., 
2011).  
While eCBs and CB1 have been shown to modulate CCK+INs in multiple brain areas 
(Chhatwal et al., 2009; Szabo et al., 2014), the mechanisms by which they modulate 
neurotransmitter release and CaVs is not completely understood (Lozovaya, Min, Tsintsadze, & 
Burnashev, 2009). N-type CaVs (CaV2.2) and CB1 are localized in CCK+INs and often found in 
regulatory nanodomains, indicating they have a strong functional linking (Dudok et al., 2015). 
Studies have revealed complex regulatory roles of CB1 and eCBs on CaV2.2 in the HPC. Lenkey 
and colleagues (2015) observed that in the CA3 region of the HPC, tonic eCB-mediated activation 
in CCK+INs resulted in reduced Ca2+ entry through CaV2.2, independent of CB1 content. Lenkey 
and colleagues (2015) also observed that only the CB1 receptors located within 1 nm of Cav2.2 
were responsible for eCB-mediated modulation of GABA release (Lenkey et al., 2015). 
Additionally, CCK+INs in the CA1 region of the HPC were reported to experience CB1-mediated 
tonic inhibition of GABA release, disrupting perisomatic inhibition networks (Neu et al., 2007).  
It is not known whether the eCB-dependent and eCB-independent mechanisms observed 
in the HPC are conserved in CCK+INs in the BLA. If conserved, CB1 may modulate anxiety at 
the level of the BLA, indicating eCBs, CB1, and CaV2.2 can possibly be targets of neuromodulators 
with anxiolytic properties. In this study, we aim to visualize CB1 receptors in CCK+INs of the 
BLA and characterize their inhibition (phasic and/or tonic) of P-cells. If present, we aim to 
determine how CaV2.2 modulates eCB-mediated inhibition. We expect our experiments will reveal 
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more information on the contribution of eCBs and CB1 to neurotransmitter release in CCK+IN/P-





Refer to CHAPTER 1 for detailed information on the breeding, background, and research 
applications of our CCK-Dlx5/6-tdT and CCK-Dlx5/6-ReaChR mouse models. CCK-Dlx5/6-tdT 
mice were used in immunofluorescence experiments to visualize CCK+IN and CB1 expression 
and colocalization in the BLA and HPC. CCK-Dlx5/6-ReaChR mice were used in 
electrophysiology experiments to study the role of CB1 in CCK+IN/P-cell synapses in the BLA. 
 
Immunofluorescence  
 Adult CCK-Dlx5/6-tdT mice were deeply anesthetized with isoflurane (07-893-1389; 
Patterson Veterinary) and given an intraperitoneal injection of Euthasol euthanasia solution 
(710101; Virbac Co.). Whole animal perfusion fixations were performed using formalin solution 
(HT501128; Sigma-Aldrich). Brains were rapidly dissected and stored at 4°C in formalin solution 
for 24-72 hours for further fixation. 80-100 µm coronal brain slices containing the amygdala and 
hippocampus were prepared using a vibratome (VT1000 S; Leica) and transferred to a 12-well 
plate (Greiner Bio-One). Slices were gently washed once in PBS and twice in 1% PBT (1% Triton 
X (T8787; Sigma-Aldrich) in PBS (P3813; Sigma-Aldrich)) for 10 minutes per wash on an orbital 
rocker (SK-O180-S; Scilogex). Slices were blocked in a 5% bovine serum albumin/PBT (5% 
BSA/PBT) solution for two hours at room temperature. After blocking, slices were washed three 
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times in 1% PBT before primary antibody incubation in a 1:200 dilution of anti-CB1 antibody 
(ab23703; Abcam) and 5% BSA/PBT for 24-36 hours at 4°C. Following primary antibody 
incubation, slices were washed three times in 1% PBT and incubated in goat anti-rabbit Alexa 488 
(ab150077; Abcam) secondary antibody for four hours at room temperature. After secondary 
antibody staining, slices were washed twice in 1% PBT and once in PBS before mounting onto 
micro slides (48311-703; VWR) with Vectashield medium (H-1400; Vector Laboratories) and 
micro cover glass (48393-221; VWR). Slides were stored at 4°C for a minimum of 24 hours before 
confocal imaging. 
 
Confocal Imaging and Colocalization Quantification  
Confocal microscopy on immunostained brain slices was completed using a Zeiss LSM 
510 Meta. Multi-track acquisition with argon and helium-neon lasers was used to acquire images 
without excitation cross-talk. A series of band- and long-pass filters were applied to capture 
isolated emission peaks from individual fluorophores and prevent emission cross-talk. 
Fluorophores and their spectra (excitation/emission (nm)) were Alexa 488 (490/525) and tdTomato 
(554/581). Images were set to either a 1024 x 1024 or 2048 x 2048 frame size. A left-to-right scan 
with line averaging was used, each line being scanned eight times. The camera pinhole was kept 
at 1 airy unit across all imaging. Range indication was used to adjust the amplifier offset and 
detector gain, preventing over/under saturation of signals. A combination of tile-scans, z-scans, 
and single-plane images were taken at 5x, 10x, 20x, 40x, and 63x.  
CB1/CCK colocalization analysis was conducted with Carl Zeiss LSM Software (version 
3.2). Single plane images of the BLA and the HPC were taken in the same brain slice using 
identical amplifier offset and detector gain settings to standardize fluorescence intensity. Intensity 
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thresholds were set using two different methods. First, intensity thresholds were manually set for 
green and red channels as to only include fluorescence in cell bodies/neuronal processes and 
exclude background signal. Second, intensity thresholds were automatically set using the Costes 
automated method, which computes the average intensity and standard deviation based off of a 
background ROI (an unlabeled cell body without observable CCK/CB1 innervation). Of the two 
intensity threshold methods, our colocalization calculations were based off the Costes automated 
method as to prevent experimenter biases in threshold selection. Colocalization cut masks images 
were produced using this threshold in which only pixels containing colocalized CCK and CB1 
expression are displayed. The Mander’s unweighted colocalization coefficient (MCC) and 
Pearson’s correlation coefficient (PCC) were used to quantify colocalization and generated using 
the Costes automated method.  
 
Electrophysiology  
Refer to CHAPTER 1 for specific details on in vitro brain slice preparation and 
electrophysiology, as we applied the same protocols up to the point of pharmacological additions. 
Briefly, whole-cell voltage-clamp electrophysiology was performed on P-cells in the BLA of an 
adult CCK-Dlx5/6-ReaChR female. GABA release was evoked from CCK+INs every fifteen 
seconds through optogenetic stimulation of ReaChR channels and IPSCs were recorded in 
proximal P-cells. A baseline IPSC peak amplitude was established over several minutes before 
pharmacological additions were performed. AM251 (1117; Tocris Bioscience), a potent CB1 
antagonist, was used to study the role of tonic inhibition in CCK+IN/P-cell synapses in the BLA. 
AM251 (10 µM) was added to the bath perfusion and IPSCs were continually evoked until no 
further changes in peak amplitude were observable. The brain slice was discarded, and equipment 
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was thoroughly cleaned. An additional brain slice was placed into the recording chamber with 
fresh aCSF. Baseline IPSC peak amplitude was again established before the addition of 2-AG (20 
µM) to the bath perfusion. 2-AG (53847-30-6; Tocris Bioscience) is an endogenous cannabinoid 
which we used to study the role of phasic inhibition in CCK+IN/P-cell synapses in the BLA. After 
recordings were finished, we determined if there were changes to average IPSC peak amplitude 
under control, 2-AG, and AM251 conditions.  
 
Electrophysiology Data Analysis 
The effects of CB1 agonism and antagonism on IPSC peak amplitude in CCK+IN/P-cell 
synapses in the BLA were studied in two cells from a female CCK-Dlx5/6-ReaChR mouse. As 
described in CHAPTER 1, representative IPSC traces, time-course plots, and two-point segment 
plots were generated in Origin 6.1. Representative traces were plotted to compare control condition 
IPSCs to those under 2-AG and AM251 conditions. Peak amplitudes were used as a quantitative 
representation of the amount of GABA release from presynaptic CCK+INs and were calculated by 
subtracting baseline sweep current (pre-IPSC) from the maximum positive-going current of the 
sweep, which occurred just milliseconds after LED stimulation. Time-course plots were generated 
to illustrate the effects of 2-AG and AM251 on peak amplitude. Two-point segment plots were 
created to compare average IPSC peak amplitude under control, 2-AG, and AM251 conditions. 
Average peak amplitudes for the two pharmacological conditions were determined only after the 
point at which IPSCs had stabilized in the time-course plot, approximately ten minutes after 




CB1 Expression in CCK+INs in the BLA and Hippocampus 
 Confocal images of immunofluorescence in CCK-Dlx5/6-tdT brain slices display 
widespread CB1 and CCK expression in the BLA and the HPC (CA3 region) (Figure 14A - 
left/middle). CB1 is labelled with the Alexa 488 (green) fluorophore through secondary/indirect 
immunofluorescence while CCK+INs are labelled with tdTomato (red) through dual recombinase 
action (see Figure 9A for intersectional strategy). In Figure 14A - left, three CCK+INs are seen 
in the midst of several non-labelled cell bodies (black circles) in the BLA. Due to their bulbous 
morphology and dense fluorescence, it appears there are an abundance of GABAergic CCK+ 
terminals in peripheral tissue and around cell bodies. Several thick neuronal processes, likely 
primary dendrites, can be seen in the right-hand side of Figure 14A - left. Thinner neuronal 
processes, likely the secondary and tertiary dendrites of CCK+INs, are present throughout the 
tissue. Also seen throughout the tissue are CB1-contaning neuronal processes, which are especially 
prevalent encircling CCK+INs in Figure 14A - left/middle. CB1 expression appears to be present 
in thinner projections, likely secondary/tertiary dendrites and terminals. There is no Alexa 488 
fluorescence within cell bodies, as CB1 is expressed in the transmembrane domain. There is minor 
colocalized signal around the center of the CCK+INs in Figure 14A - left/middle as well as in 
what appear to be the processes around non-labelled cell bodies. A cut mask image generated in 
Carl Zeiss LSM Software depicts colocalization of tdTomato and Alexa 488 fluorescence Figure 
14A - right. Colocalization patterns suggest that synaptic terminals are areas of high combined 
CCK/CB1 expression. Some neuronal processes, possibly secondary dendrites, also show 
colocalization, albeit at a lower level than synaptic terminals. 
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Figure 14B - left/middle depicts fluorescence representing CCK+IN and CB1 expression 
in the CA3 region of the HPC in CCK-Dlx5/6-tdT brain slices. Figure 14B - left contains one 
CCK+IN with what appears to be high levels of innervation of cells in the stratum pyramidale (SP) 
layer. Many cells in the SP are innervated by CCK+IN projections. Additionally, CCK+IN 
projections are observable in the transition between the SP and the stratum lucidum (SL), and to a 
lesser extent in the larger SL layer. CB1 expression patterns are similar here as in the SP, but with 
a greater degree of intensity. In the SP, CB1 appears to be expressed in the synaptic terminals that 
comprise perisomatic inhibition patterns (Figure 14B - left). CB1 is also expressed in neuronal 
processes which weave in and around cells. Based on morphology, there are many presynaptic 
terminals that express CB1. Expression appears to be concentrated on either side of the SP. In the 
SL, CB1 expression is weaker, as seen in the right-hand side of Figure 14B - left. Faint Alexa 488 
fluorescence is observable in what are probably secondary/tertiary dendrites and synaptic terminals. 
Figure 14B - middle depicts a CCK+IN and CB1 expression in the SL layer of CA3. Immediately 
visible are the thicker dendritic processes containing CB1 expression. They run throughout the 
tissue but are noticeably denser in the top portion of Figure 14B - middle, close to the SP-SL 
transition. The cut mask in Figure 14B - right reveals that CCK/CB1 colocalization is mild in the 
stratum oriens (SO), moderate in the SL, and strong in the SP. Not every cell in the SP is innervated 
by CCK+INs/CB1, as some are indistinguishable from one another like in the lower center portion 
of Figure 14B - right.  
Pearson’s correlation coefficient (PCC) was used to measure overall colocalization (R) of 
CCK and CB1 expression (Figure 14A/B - right). In the BLA, we obtained an R-value of 0.79 and 
in the HPC, an R-value of 0.84. We also calculated the Mander’s unweighted colocalization 
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coefficient (MCC) for CCK/CB1 signal in these two brain regions. We obtained an MCC of .783 
in the BLA and .589 in the HPC.  
 
Figure 14| GABAergic CCK and CB1 expression in the BLA and HPC. Confocal images taken of 
immunofluorescence in coronal brain slices from adult CCK-Dlx5/6-tdT mice. CCK+INs and their 
projections are tagged with tdTomato (red) while the type-1 cannabinoid receptor (CB1) is tagged with 
Alexa 488 (green). Scale is applicable to every images within the figure, as identical settings were used to 
capture each image. A| GABAergic CCK and CB1 expression in the basolateral amygdala. Left: CB1 and 
GABAergic CCK are expressed in what appear to be synaptic terminals, indicated by small circular areas 
of high fluorescence. Fluorescence is also concentrated around cell bodies (black circles) in what appear to 
be perisomatic inhibition patterns. Areas of yellow signal contain both Alexa 488 and tdTomato 
fluorescence (colocalization). Middle: A CCK+IN is surrounded by what appear to be CB1-containing 
terminals. Right: A colocalization cut mask displaying only pixels which contain colocalized GABAergic 
CCK and CB1 expression. Non-colocalized pixels are set to zero intensity. B| GABAergic CCK and CB1 
expression in the CA3 region of the hippocampus (HPC). GABAergic CCK and CB1-containing processes 
innervate many cells and colocalize around cell bodies. Left: In the HPC, what appear to be CB1-containing 
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terminals innervate the stratum pyramidale, lucidum, and radiatum layers. Innervation by the CCK+IN 
displays similar patterns. Colocalization can be seen in multiple perisomatic inhibition-like circuits. Middle: 
A CCK+IN in the stratum radiatum layer of CA3 is appears to be innervated by CB1-containing terminals. 
Neuronal processes containing CB1 are seen in the surrounding tissue. Right: A colocalization cut mask 
displaying only pixels which contain colocalized GABAergic CCK and CB1 expression in CA3. 
 
CB1 Agonist (2-AG) Reduced IPSC Peak Amplitude in CCK+IN/P-cell Synapses in the BLA  
We observed that the CB1 agonist, 2-AG, reduced IPSC peak amplitude in CCK+IN/P-cell 
synapses in the BLA of an adult female CCK-Dlx5/6-ReaChR mouse. Addition of 2-AG to the 
bath perfusion decreased peak amplitude over a fifteen-minute recording (Figure 15A). A control-
condition trace (black) and a 2-AG-condition trace (forest) are plotted in Figure 15A - left to 
represent the differences in peak amplitude. The gradual decrease in IPSC peak amplitude 
following addition of 2-AG (20 µM) to the bath perfusion is displayed in a time-course plot 
(Figure 15A - middle). 2-AG exerted its full effects eight minutes after addition. The change in 
average IPSC peak amplitude before and after 2-AG addition is represented by a two-point 
segment plot (Figure 15A - right). The pair of white circles represent the average peak amplitude 
before and after 2-AG addition. The average IPSC peak amplitude under control conditions is 225 
pA and 167 pA after 2-AG addition (26% decrease).  
 
CB1 Antagonist (AM251) Increased IPSC Peak Amplitude in CCK+IN/P-cell Synapses in the BLA 
One P-cell was patched and recorded from the BLA of an adult female CCK-Dlx5/6-
ReaChR mouse. AM251 applied to the bath perfusion (10 µM) increased IPSC peak amplitude in 
a CCK+IN/P-cell synapse in the BLA (Figure 15B). Representative traces depicting changes in 
IPSC peak amplitude are plotted in Figure 15B - left. The control trace (black) is 175 pA while 
the AM251conditions trace (brown) is 225 pA. The gradual increase in IPSC peak amplitude 
following AM251 addition is displayed in a time-course plot (Figure 15B - middle). Stable IPSCs 
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were evoked for thirteen minutes before AM251 addition, after which peak amplitude began to 
increase, plateauing by minute twenty-three. The average IPSC peak amplitudes under control and 
AM251 conditions are represented in a two-point segment plot (Figure 15B - right). The first circle 
is the average peak amplitude under control conditions (170 pA), while the second circle is the 
average peak amplitude under AM251 conditions (229 pA).  
 
Figure 15| Effects of CB1 modulation in CCK+IN/P-cell synapses in the BLA. Optogenetically-evoked 
IPSC were recorded in adult CCK-Dlx5/6-ReaChR brain slices. Scale bars indicate time and current values 
for IPSC traces. Drug conditions are indicated in the color-coded timelines. A| Effects of CB1 agonism on 
IPSCs in CCK+IN/P-cell synapses. Left: Representative IPSC traces under control (black) and 2-AG (forest 
green) conditions. Middle: Time-course plot of IPSC peak amplitude in response to bath addition of 2-AG 
(20 µM). 2-AG was added at 2 min and showed full effects by 10 min. Right: Average IPSC peak amplitude 
under control and 2-AG conditions. Peak amplitude decreased from 225 pA to 167 pA (-26%). B| Effects 
of CB1 antagonism on IPSCs in CCK+IN/P-cell synapses. Left: Representative IPSC traces under control 
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(black) and AM251 (brown) conditions. Middle: Time-course plot of IPSC peak amplitude in response to 
bath addition of AM251 (10 µM). AM251 was added at 13 min and showed full effects by 23 min. Right: 
Average IPSC peak amplitude under control and AM251 conditions. Peak amplitude increased from 170 
pA to 229 pA (+34%).  
 
Discussion 
Expression of CB1 in CCK+INs in the BLA and HPC 
To quantify colocalization, we report both PCC and unweighted MCC values, each of 
which has strengths and shortcomings (Dunn, Kamocka, & McDonald, 2011). By obtaining the 
unweighted MCC values for tdTomato and Alexa 488 expression in the BLA and HPC, we 
acknowledge that the two fluorophores have different intrinsic brightness properties. Unweighted 
MCC values are based on pixel population rather than intensity (Adler & Parmryd, 2010), therefore 
they provide a better representation of the amount of CCK+IN/CB1 content in tissue. We did not 
expect to find unweighted MCC values close or equal to one, as this would indicate every pixel 
containing tdTomato fluorescence also contains Alexa 488 fluorescence, represented by total 
colocalization (yellow signal) across the entire image. Additionally, a cut mask analysis would 
recreate the entire two-channel overlay image, converting red and green signals to yellow based 
on the intensity of their colocalization. In both the BLA and HPC we find areas of either no or sub-
threshold colocalization, represented by black spaces in Figure 14A/B - right. Along similar lines, 
we did not expect to find unweighted MCC values approaching zero, indicative of perfectly 
opposite tdTomato and Alexa 488 patterns (no colocalization) (Everett, 2016). In addition to MCC 
values, we obtained PCC values with the Costes automated method (Costes et al., 2004). PCCs 
values are free of the influence of experimenter bias, as fluorescence threshold value cannot be 
manually set. If tdTomato and Alexa 488 fluorescence are perfectly linearly related, we would 
expect a PCC value of one, and if they perfectly inversely related, we would expect a PPC value 
of negative one.  
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While direct colocalization analysis has not been performed between CCK+INs and CB1 
in brain slices containing the BLA, previous mRNA and protein studies demonstrate a moderate-
high degree (61-88%) of colocalization between CB1 and CCK (Chhatwal et al., 2009; McDonald 
& Mascagni, 2001). We obtain a PCC value of 0.79 and an MCC value of 0.783, meaning 62% 
(PCC2) and 78% (MCC) of the variability in CB1 (Alexa 488) fluorescence can be explained by 
the variability in GABAergic CCK (tdTomato) fluorescence. Despite being done in a novel system, 
these colocalization result falls within the range of reported CB1 and CCK colocalization values 
for the BLA (Chhatwal et al., 2009; McDonald & Mascagni, 2001).  
It has been previously reported that CB1 is present in 82.7% of CCK+ terminals in the CA3 
region of the HPC (Foldy, 2006). Furthermore, a majority of CB1 terminals in the SP layer 
innervate P-cells while those in SO/SR layers target dendrites (Foldy, 2006). Our cut mask analysis 
appears to qualitatively reflect these finding (Figure 14B - right). In the HPC, we obtain a PCC of 
0.84 and an MCC value of 0.589, meaning 71% (PCC2) and 59% (MCC) of the variability in CB1 
(Alexa 488) fluorescence can be explained by the variability in GABAergic CCK (tdTomato) 
fluorescence. I predict this variability to be due to the sensitivity of the MCC to the estimate of 
background. A decrease by just one gray level has been associated with a 2% decrease in the overall 
estimated overlap of signal in MCC analysis (Dunn et al., 2011). If considering PCC analysis only, 
then our R2 value of 71% value is 12% percentage points lower than reported co-expression levels 
(Katona et al., 1999). This may be due to variations in technique (i.e. confocal vs electron 
microscopy, immunoperoxidase vs immunofluorescence), or suggest that CCK/CB1 colocalization 
highly variable. 
There are no direct comparisons of CCK/CB1 colocalization between the BLA and HPC 
using brain slice immunofluorescence. However, across multiple studies with only minor 
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variations in reported expression value, it is clear that GABAergic CCK and CB1 expression are 
highly linked in structures like the BLA, HPC, and PFC (Eggan, Melchitzky, Sesack, Fish, & 
Lewis, 2010; Katona et al., 1999; Shen, Piser, Seybold, & Thayer, 1996). Between our 
colocalization analysis of the BLA and HPC, PCC values are 9% apart while MCC values are 19% 
apart. As described above, MCC values are not ideal for our images, but could hold value if we 
had lower levels of background Alexa 488 expression. PCC values, while limited in their 
application, provide us with non-subjective background determinations. Given that both cut masks 
analyses in Figure 14A/B - right were performed using identical detection settings and in the same 
brain slice, PCC values present the most controlled measure of overall CCK/CB1 colocalization.  
 
Phasic CB1-mediated Inhibition of GABA Release in CCK+IN/P-cell Synapses in the BLA  
 We observe a 26% decrease in IPSC peak amplitude (from 224 pA down to 167 pA) when 
CCK+IN/P-cell synapses in the BLA were exposed to 2-AG (Figure 15A - right). While our n-
value is not large enough to determine significance, our preliminary finding aligns with what 
Rovira-Esteban and colleagues (2017) report. IPSC peak amplitude has been shown to be inhibited 
by application of synthetic CB1 agonists in the BLA previously (Katona et al., 2001). Activity of 
2-AG, the endogenous CB1 agonist, can be studied by direct application of the agonist, or by 
stimulating the synthesis of the agonist in the postsynaptic cell (Yoshida et al., 2011). The latter 
method is used by Rovira-Esteban and colleagues (2017) to study transmission from CCK+INs in 
the basal amygdala. In order to draw comparisons between their study and ours, the differences in 
experimental design must be made apparent.  
2-AG is synthesized in postsynaptic cells following depolarization, and retroactively binds 
to presynaptic terminals to suppress transmitter release in a system of negative feedback inhibition 
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(Zhu, 2005). The mechanism by which 2-AG is synthesized in P-cells and activates CB1 in 
presynaptic terminals is known as depolarization-induced suppression of inhibition (DSI), while 
the manner in which CB1 then inhibits transmitter release is known as phasic inhibition (Guo & 
Ikeda, 2004; Wilson et al., 2001). Rovira-Esteban and colleagues (2017) used DSI to study eCB-
mediated inactivation of GABA release, whereas we used direct addition of 2-AG to the bath 
perfusion to study phasic inhibition in the same cellular circuit. Rovira-Esteban and colleagues 
(2017) demonstrate that the actions of 2-AG significantly reduce IPSC peak amplitude to 32% (+/-
7%) compared to baseline. Our 26% decrease is not as great in magnitude; however it is a 
preliminary indicator that eCB-dependent phasic CB1 inhibition of transmitter release in 
CCK+IN/P-cell synapses of the BLA is a reproducible finding.  
 
Tonic CB1-mediated Inhibition of GABA Release in CCK+IN/P-cell Synapses in the BLA  
We present a recording where IPSC peak amplitude increases by 34% in response to bath 
addition of AM251 (Figure 15B - right). As a CB1 antagonist, AM251 blocks phasic, eCB-
dependent inhibition of CaVs (Lenkey et al., 2015). However, CB1 does not require eCBs to 
downregulate CaVs (tonic inhibition). AM251 also blocks tonic CB1 inhibition of CaVs, reducing 
the probability of GABA release onto postsynaptic P-cells (Biro, Holderith, & Nusser, 2006; 
Delaney, Crane, & Sah, 2007). In addition to blocking tonic CB1-mediated inhibition of CaV2.2 
and increasing GABA release probability, it has been proposed that AM251 increases the number 
of GABAergic exocytosis cites (Biro et al., 2006; Delaney et al., 2007; Rovira-Esteban et al., 2017). 
This would allow for a greater amount of GABA release from CCK+INs, represented by stronger 
chloride flow and subsequently greater IPSC peak amplitude in postsynaptic P-cells.  
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Similar to our observation of 34% increase, Rovira-Esteban and colleagues (2017) report 
a 45% increase in IPSC amplitude upon AM251 addition in CCK+IN/P-cell synapses in the BLA. 
The 11% discrepancy despite being from the same circuits can be potentially explained in several 
ways. Rovira-Esteban and colleagues (2017) have an n-value of 10, whereas we obtained an n-
value of 1 before their paper was released. Additionally, a 34% increase falls within their reported 
standard deviations. We controlled for variables that could have given us false confirmation of 
their observations. For example, with too high a concentration of AM251, we may have observed 
a stronger increase in IPSC peak amplitude. The peak amplitude increase we observed with 10 µM 
proved to be lower, but within deviation range, of the increase Rovira-Esteban and colleagues 
(2017) observed using a 5 µM dose. Overall, our mouse line and initial experiments serve as a tool 
for further studies on the molecular components underlying CB1-mediated inhibition in the BLA. 
 
Additional Considerations for Future Research 
 Our future interests center on describing the regulatory role CB1 exhibits on CaV2.2 
channels in specific cell populations in the BLA (see NIH: R00-MH099405). Ideally, we aim to 
prove that CB1 inhibits CaV2.2 channels to control transmission in CCK+IN/P-cell synapses. If 
present, CB1-mediated inhibition of CaV2.2 would demonstrate tonic inhibition in the BLA, as it 
occurs independent of eCBs. To accomplish this, we would perform electrophysiology recordings 
from P-cells and quantify the component of IPSCs that is sensitive to ω-Conotoxin GVIA under 
the presence of AM 251. Additionally, we aim to show that eCBs acting through CB1 are powerful 
anxiolytics via their inhibition of CaV2.2 channels in amygdala synapses. eCB-mediated 
modulation of CaV2.2 would be considered phasic inhibition, as it is ligand-dependent and short-
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term, dissipating after eCBs have been cleared from the presynaptic terminal. This system can be 
studied through DSI experimentation as described by Ramikie and Patel (2012). 
Additionally, we propose to study if CB1-mediated inhibition of CaV2.2-dependent 
GABAergic release in the BLA is elevated during anxiety states. Behavioral studies like repetitive 
stress models, intended to induce anxiety-like behavior, have shown long-lasting changes to the 
eCB system in several brain areas including the BLA (M. N. Hill et al., 2010; Hill et al., 2009; 
Lafenêtre, Chaouloff, & Marsicano, 2007; Patel et al., 2009; Patel, Roelke, Rademacher, & Hillard, 
2005; Qin et al., 2015; Viveros, Marco, & File, 2005). Additionally, anxiety is linked to reduced 
GABAergic transmission in the BLA (Ehrlich et al., 2009). Postsynaptic modulations have been 
observed during anxiety, but little has been shown regarding the impact of anxiogenic stimuli on 
effectors of CB1, like CaV2.2 channels. It may be the case that that anxiety states cause enhanced 
CB1 inhibition of CaV2.2 channels in CCK+INs. To determine this, we will put mice through an 
established anxiety-inducing behavioral paradigm and measure IPSCs in CCK+IN/P-cells 
synapses to assess the levels of phasic and tonic inhibition between anxious and non-anxious 




CHAPTER 3: ASSESSING REGULATION OF GABA RELEASE AND INTRINSIC 
FIRING BY CAV2.2 IN THE INFRALIMBIC CORTEX 
Abstract 
 The medial prefrontal cortex (mPFC) is an area of the brain involved in emotional 
processing. Rodent studies have demonstrated that neuronal output from the mPFC is crucial for 
the expression and conditioning of fear. Disruptions in the activity of the mPFC are associated 
with deficits in fear extinction, a process which is also disrupted by anxiety disorders like post-
traumatic stress. Chronic and traumatic stress have been shown to negatively impact the mPFC at 
the cellular level; pyramidal cells (P-cells), the primary excitatory projections in the mPFC, 
become unstable and less responsive. In turn, the brain regions which are innervated by these P-
cells are adversely affected. The resultant behavioral consequences vary depending upon the 
connection type. A sub-region of the mPFC known as the infralimbic cortex (IL) is involved in 
extinction memory. The IL is organized into multiple layers in which P-cells establish connections 
with the basolateral amygdala (BLA). The BLA is crucial for normal fear-related learning, 
particularly fear acquisition and fear extinction. Irregular activity in the connections between the 
IL and the BLA promote insufficient fear regulation and responses, however the underlying 
cellular physiology is not well understood. To help better understand the neurobiology of fear 
processing and anxiety disorders, we targeted the N-type calcium channel (CaV2.2) in this study. 
In limbic structures like the hippocampus, these channels have been shown to be expressed in the 
presynaptic terminal of cholecystokinin-positive interneurons (CCK+INs) and in P-cells, coupled 
to calcium-activated potassium channels. However, no data has been presented describing if these 
CaV2.2 roles are conserved within the IL. A series of electrophysiology and confocal microscopy 
experiments were conducted to study presynaptic and somatic CaV2.2 in the IL. We determined 
that inhibitory postsynaptic currents (IPSCs) in GABAergic/P-cell synapses are significantly 
reduced (46%) following CaV2.2 blockade (p = .00015). We found that CaV2.2 blockade had no 
significant effect on the firing properties of P-cells (p = .204). Confocal images depicted densely 
innervated P-cells in layers 2, 3, and 5. Electrophysiological studies revealed that the peak 
amplitude of IPSCs in CCK+IN/P-cell synapses is not significantly affected by CaV2.2 blockade 
(p = .122). We conclude that neurotransmitter release is partially CaV2.2-dependent in 
GABAergic/P-cell synapses and not significantly CaV2.2-dependent in CCK+IN/P-cell synapses 
in the IL, suggesting other voltage-gated calcium channel subtypes (CaVs) are involved. Our 
findings serve as a foundation for further research into the cellular mechanisms underlying anxiety-
related circuits in the IL.  
 
Introduction 
 The medial prefrontal cortex (mPFC) is involved in the processing and behavioral 
responses to fear and anxiety. Of the multiple sub-regions that comprise the mPFC, two areas in 
particular are of interest to researchers for their differentiable effects on anxiety-like behavior 
(Sierra-Mercado et al., 2011). The prelimbic region of the mPFC (PL) facilitates behavioral 
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responses to fearful stimuli (fear expression) through its interconnections with the basolateral 
amygdala (BLA) (Sullivan & Gratton, 2002). Ventral to the PL, the infralimbic region of the mPFC 
(IL) is involved in extinction of conditioned fear, a product of extinction-related neuronal plasticity 
in the hippocampus (HPC) and BLA (Do-Monte et al., 2015). Dysfunction in mPFC-amygdala 
pathways are observable in patients with anxiety disorders. Deficient recruitment of the mPFC is 
observed during the process of fear inhibition in patients with generalized anxiety disorder (GAD) 
(Greenberg et al., 2013). Patients with post-traumatic stress disorder (PTSD) exhibit decreased 
mPFC activation and increased amygdala activation in response to trauma-related cues (Shin et al., 
2004). Additionally, reduced mPFC activity in PTSD has been associated with impaired fear 
extinction recall (Bremner et al., 2005) and greater symptom severity (Shin et al., 2005). In animal 
models, mPFC function has been associated with the expression of anxiety-like behaviors and the 
extinction of conditioned fear, both of which can be impaired with selective inactivation of the 
mPFC (Sierra-Mercado et al., 2006, 2011). Neuronal models of anxiety disorders have led to the 
belief that reduced mPFC function, in combination with over-excitation in the amygdala, mediate 
the dysregulation of fear responses (Rauch, Shin, & Wright, 2006). While the anxiety-related 
behavioral components of these connections have been extensively studied, their underlying 
neurobiology is less understood.  
The process of fear extinction is of great concern for treating anxiety disorders like PTSD 
(Johansen et al., 2011; Shin et al., 2004) as sufferers are unable to extinguish anxiety-inducing 
memories developed in response to previous trauma. Accordingly, understanding the molecular 
mechanisms underlying IL-BLA connections may provide insight as how anxiety-related neuronal 
output is regulated (Johansen et al., 2011). In mice, the IL is divided into multiple layers (L1, L2/3, 
L5, and L6) based on cell types, projections, and local circuit organization (Allene, Lourenço, & 
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Bacci, 2015; Allen Mouse Brain Atlas). Across layers, a majority of neurons are excitatory P-cells 
(approximately 80%), while a minority are inhibitory interneurons (INs), including basket cells 
(BCs), dendritic cells, and axo-axonic cells (Allene et al., 2015; Riga et al., 2014). P-cells can be 
found in L2/3, L5, and L6 while INs are found within every layer (Cruikshank et al., 2012; Ma, 
Yao, Fu, & Yu, 2014; Riga et al., 2014). The projections from P-cells in L5/L6 are deep, generally 
targeting subcortical areas, while the projections from L2/3 are more superficial, generally 
targeting other cortical areas (Douglas & Martin, 2004). The intrinsic properties and circuit 
organization of these cells is of interest, as regulating their interactivity is required for normal fear 
and anxiety-related processing (Sierra-Mercado et al., 2006). P-cells in L2/3 and L5 are known to 
make reciprocal connections with the BLA (Allene et al., 2015; Ferreira et al., 2015). IL-BLA 
connections receive various excitatory inputs, primarily from the contralateral mPFC, midline 
thalamic nucleus, BLA, and ventral HPC (Riga et al., 2014). Additionally, IL-BLA connections 
receive various inhibitory inputs, which present themselves as targets for potentially mediating 
fear extinction at the level of the IL (Do-Monte et al., 2015). 
Two major forms of inhibition are exerted upon IL-BLA projections (Allene et al., 2015). 
Dendritic inhibition of P-cells is facilitated by Martinotti cells and neurogliaform cells, two IN 
subtypes located in L2/3-L6 and L1, respectively (Palmer, Murayama, & Larkum, 2012; Y. Wang 
et al., 2004). Perisomatic inhibition is facilitated by parvalbumin-containing (PV+) and 
cholecystokinin-containing (CCK+) basket cells (BCs), two additional IN subtypes which synapse 
onto the soma of local P-cells (Freund, 2003; Freund & Katona, 2007). Dendritic inhibition can be 
evoked in a feed-forward manner by afferent projections. For example, thalamic input has been 
shown to excite dendritic INs in L1, which then inhibit P-cells in L2/3 (Cruikshank et al., 2012). 
Perisomatic inhibition is a form of feedback inhibition, where the firing of P-cells stimulates local 
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BCs to then regulate P-cell activity. Whereas the role of PV+BCs in perisomatic inhibition has 
been studied in L2/3, L5, and L6 (layers containing IL-BLA projections), the role of CCK+BCs in 
the same circuits has not (Allene et al., 2015; Armstrong & Soltesz, 2012; Freund, 2003). 
Research suggests that in cortical regions, voltage-gated calcium channels (CaVs) are 
involved in regulating GABA release from INs and the intrinsic firing properties of P-cells 
(Ferreira et al., 2015; Freund, 2003; Jasnow et al., 2009; Kurihara & Tanabe, 2003; Loane et al., 
2007). However, the role of CaVs in specifically the IL has not been functionally investigated, 
representing an important target by which anxiety may be regulated. Of the multiple CaV subtypes, 
N-type CaVs (CaV2.2) are distinguished for their anxiety correlation (Lotarski et al., 2011). GABA 
release from presynaptic INs was shown to be entirely dependent on CaV2.2 in the HPC (Szabo et 
al., 2014), but it is not known if this is conserved in the IL. Additionally in the HPC, CaV2.2 was 
shown to modulate the intrinsic firing of P-cells through coupling to calcium-activated potassium 
channels (Loane et al., 2007). CaV2.2 is also involved in the intrinsic firing of P-cells in the deep 
cerebellar nuclei, selectively regulating their spontaneous activity (Alviña & Khodakhah, 2008). 
As is the case for the presynaptic region, it has not been determined if these intrinsic roles of 
CaV2.2 are conserved in the IL. 
The CaVs associated with GABA release from the multiple IN subtypes found in the IL 
have not been fully detailed. PV+BCs, Martinotti cells, and neurogliaform cells have been shown 
to express P/Q-type CaVs (Bartos & Elgueta, 2012), L-type CaVs (Wang et al., 2004), and further 
L-type CaVs (Li, Stewart, Canepari, & Capogna, 2014), respectively. On the other hand, the 
expression of CaV2.2 has been found in CCK+INs in the BLA, HPC, and mPFC (Ali, 2011; Eggan 
et al., 2010; Freund, 2003; Jasnow et al., 2009). GABA release from CCK+INs in the HPC was 
determined to be entirely-dependent on CaV2.2 (Szabo et al., 2014). This does not imply that 
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CCK+INs in the IL will function in the same manner however, as there are known variations in 
CCK+IN properties across brain regions, potentially due to ion channel variations (Kullmann, 
2011). GABA release from two additional IN subtypes, chandelier and bipolar cells, has not been 
associated with any CaV subtype(s). In the IL, chandelier cells form inhibitory connections on the 
axon-initial segment of P-cells, while bipolar cells are thought to inhibit other INs (Allene et al., 
2015). Little is known about the synaptic properties of these INs, and their CaV-dependency has 
yet to be determined for the IL.  
Ultimately, there is a lack of direct functional studies on the role of CaV2.2 in the 
infralimbic cortex. Our goal is to determine this role, specifically in 1) GABA release from the 
general population of INs onto P-cells in L2/3, 2) GABA release from local CCK+INs onto P-cells 
in L2/3, and 3) the firing pattern and spike frequency of P-cells in L2/3. We hope this work will 
contribute to the overall understanding of the molecular mechanisms underlying P-cell regulation 
in the IL, regulation which is crucial for normal fear extinction processes and is disrupted in 




 Refer to CHAPTER 1 for more detailed information on the breeding, background, and 
research applications of our CCK-Dlx5/6-tdT and CCK-Dlx5/6-ReaChR mouse models. CCK-
Dlx5/6-tdT mice were used in fluorescence experiments to visualize CCK+INs in the IL and greater 
mPFC. CCK-Dlx5/6-ReaChR mice were used in electrophysiology experiments to study the role 
of CaV2.2 in CCK+IN/P-cell synapses in the IL. Wild-type mice were used in electrophysiology 
 81 
experiments to study the role of CaV2.2 in GABAergic IN/P-cell connections as well as P-cell 
intrinsic firing properties.  
 
In Vitro Brain Slice Preparation and Electrophysiology  
Refer to CHAPTER 1 for more detailed information on the preparation of live brain slices 
for electrophysiology experiments as well as a description of our electrophysiology rig. Protocols 
and equipment were conserved in this experiment with minor modifications. Slices containing the 
mPFC (rather than the BLA) were prepared from adult wild-type in addition to CCK-Dlx5/6-
ReaChR mice.  
 
Electrophysiology - Electrical Stimulation and Recording of GABAergic IN/P-cell Connections  
 To study the role of CaV2.2 in neurotransmitter release from GABAergic INs onto P-cells 
in the IL, we determined the sensitivity of electrically-evoked IPSCs to CaV2.2-blockade via 
addition of ω-Conotoxin GVIA (CTX) (ab120215; Abcam) to the bath perfusion. To stimulate 
neurotransmitter release from GABAergic INs, we used a concentric bipolar electrode 
(CBBPF100; FH-Co), which was connected to a stimulus isolator (A365; WPI) and mounted to a 
three-axis dovetail manipulator (MX130L, Siskiyou Co) attached to our microscope stage. Coronal 
brain slices containing the mPFC were prepared from adult wild-type mice and mounted in the 
recording chamber. Figure 16 - top left demonstrates our recording approach. The concentric 
bipolar electrode was placed in the Pia/L1 of the IL (Figure 16 - top left, yellow circle) where INs 
are exclusively GABAergic (Cruikshank et al., 2012). A micropipette was used to perform whole-
cell patch-clamps on P-cells in layer 2/3 (Figure 16 - top left, red circle). Magnifying the patch, 
P-cells were distinguishable from other cell types by their piriform morphology and medial axonal 
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projections (Figure 16 - top middle, red circle). P-cells were held at 0 mV and an electrically-
evoked IPSC protocol was applied though pCLAMP 10 software. 1000 ms sweeps began every 15 
seconds in which a .1 ms electrical stimulation was delivered to the brain slice via the concentric 
bipolar electrode. The stimulus isolator was used to adjust the amperage delivered by the electrode 
as a percentage of 1 mA, allowing us to alter the initial peak amplitude of the IPSCs. Initial peak 
amplitude was set to between 200-700 pA in order to be large enough for pharmacological changes 
to be observed while remaining small enough as to not exhaust neurotransmitter release or harm 
the brain slice.  
Once satisfactory IPSCs were evoked, pharmacological recordings began. CPP (20 µM) 
and DNQX (10 µM), NDMA and AMPA/Kainate antagonists, respectively, were added to the bath 
perfusion to ensure we only recorded the GABAergic components of electrically-evoked 
neurotransmitter release. The initial few minutes of each recording was used to establish a baseline 
peak amplitude for control conditions, prior to the addition of pharmacological agents. CTX (400 
nM) was added to the bath perfusion to observe if there were any significant effects of CaV2.2 
blockade on peak amplitude. IPSCs were continually evoked until no further changes in peak 
amplitude were observable, i.e. a ‘plateau’ phase. CTX-dependent effects typically took fifteen-
twenty minutes to fully present. Next, bicuculline (BIC) (ab120107; Abcam), a GABAA antagonist, 
was added to the bath perfusion (100 µM) to eliminate IPSCs and confirm the bath perfusion was 
delivering pharmacological agents to the brain slice. Recordings (n = 6 cells) were typically 
between 45-60 minutes in length. Once a recording was finished, brain slices were discarded and 
aCSF was replaced. Electrophysiology equipment was washed thoroughly with hydrogen peroxide 
and MilliQ water to avoid pre-exposing subsequent brain slices to pharmacological agents. 
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Representative traces were plotted in Origin 6.1 to compare IPSCs evoked under control, 
CTX, and BIC conditions. Peak amplitudes, used as a quantitative representation of the amount of 
neurotransmitter release from GABAergic INs, were calculated by subtracting baseline sweep 
current (pre-IPSC) from the maximum positive-going current of the sweep which occurred just 
milliseconds after LED stimulation. A time-course plot was created to represent the changes in 
IPSC peak amplitude (pA) in response to pharmacological conditions over the duration of the 
recording (min). A two-point segment plot was created to compare average IPSC peak amplitude 
under control and CTX conditions across the six cellular recordings. Average peak amplitudes 
were determined after the point at which IPSC peak amplitude remained relatively stable in the 
time-course plot. A one-tailed paired t-Test was run comparing the average peak amplitude under 
control and CTX conditions across the six cellular recordings. The mean, standard deviation (SD), 
and standard error of the mean (SEM) for the average peak amplitude under control and CTX 
conditions across all recordings were calculated. This mean (gray circles) and SEM (vertical black 
lines) were added to the two-point segment plot. 
 
Fluorescence Stainings & Confocal Microscopy  
Refer to CHAPTER 1 for more detailed information on fluorescence and confocal imaging 
in CCK-Dlx5/6-tdT mice. Protocols and equipment were conserved in this experiment, except were 
done to section, stain, and image brain slices containing the mPFC rather than the BLA.  
 
Electrophysiology - Optogenetic Stimulation of IPSCs in CCK+IN/P-cell Synapses  
To determine the role of CaV2.2 in CCK+IN/P-cell synapses in the IL, we determined the 
sensitivity of IPSCs to CaV2.2 block via CTX. Whole-cell patch-clamp recordings were performed 
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on P-cells in the IL of adult CCK-Dlx5/6-ReaChR mice (n = 8). P-cells were held at 0 mV and 
IPSCs were evoked using optogenetic simulation. Recording protocols were programmed in 
pCLAMP 10 software. 1000 ms sweeps containing a 0.1 ms stimulation began every twenty 
seconds. ‘Control’ IPSCs were evoked for several minutes to establish a baseline peak amplitude. 
CTX (300 nM) was then added to bath perfusion. IPSCs were continually evoked until no further 
CTX-dependent change to peak amplitude were observable. BIC (100 µM) was then added to the 
bath perfusion and IPSCs were evoked until eliminated. After recordings were finished, brain 
slices were discarded and aCSF was replaced. Equipment was washed thoroughly before a 
subsequent slice was added to the chamber for further recordings Data analysis was performed in 
an identical manner as described above for electrically-evoked IPSCs. 
 
Electrophysiology - Modulation of P-Cell Intrinsic Firing Properties by Cav2.2  
 To study the role of CaV2.2 in P-cell intrinsic firing properties in the IL, we determined the 
sensitivity of action potential spike train firing pattern and spike frequency to CTX and cadmium 
chloride (CdCl2). CdCl2 is a reversible CaV antagonist which allowed us to observe if CaV subtypes 
other than CaV2.2 modulated P-cell intrinsic firing properties. Whole-cell patches were performed 
on P-cells in L2/3 of the IL in wild-type mice. A current-clamp was applied, and a ramp protocol 
was run to determine the activation threshold for each P-cell. The amount of current injected to 
evoke action potential spike trains was then set to +10 pA larger than this threshold and ranged 
from 50-120 pA across recordings. Initial firing patterns were compared to previous research 
(Faber et al., 2001; Rainnie et al., 1993; Zaitsev et al., 2012) to confirm we recording from P-cells 
and not INs. Three second square-pulse currents injections were applied every 45 seconds to 
produce action potential spike trains at an interval that was both conducive to cell health and 
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allowed for pharmacologically-induced changes to be observed. Control firing patterns and spike 
frequencies were determined over a 5-10 min period before pharmacological additions began. 
Using a valve controller (VC-6; Warner Instruments), three perfusion baths were applied in 
sequential order. Bath #1, the control condition bath, contained regular aCSF. Bath #2, the CTX 
condition bath, contained aCSF + 300 nM CTX. Bath #3, the CdCl2 condition bath, contained 
aCSF + 100 µM CdCl2. Given the slow diffusion time of CTX, bath #2 was applied for at least 20 
minutes before switching to bath #3. After CdCl2-dependent effects plateaued, we applied bath #1 
for a second time to ‘wash’ the brain slice. Washes removed CdCl2 from the perfusion and were 
used to determine if the effects we observed were due to CaV block and not damage to the cell. 
Once recordings were complete, brain slices were discarded, and equipment was washed 
thoroughly with hydrogen peroxide and MilliQ water to avoid pre-exposing subsequent slices to 
pharmacological agents. 
 Representative firing patterns from the control, CTX, and CdCl2 conditions were plotted 
in Origin 6.1. Spike frequency was calculated by diving the number of spikes in an action potential 
spike train by the duration of the current injection (three seconds). The event detection function in 
Clampex 10.6 was used to count the number of action potential spikes (or ‘events’) in each sweep. 
Spike frequencies were charted alongside the time at which the corresponding sweep began (i.e. 
sweep one = 0 min, sweep two = 0.75 min, sweep three = 1.5 min, etc.). Time-course and two-
point segment plots were created in Origin 6.1 to demonstrate represent the effects of 
pharmacological agents on spike frequency in a single recording and across all cellular recordings, 
respectively. A one-tailed paired t-Test was run comparing the average spike frequency under 
control and CTX conditions across six cellular recordings. The mean, SD, and SEM for the average 
spike frequency amplitude under control and CTX conditions across recordings were calculated. 
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This mean (gray circles) and SEM (vertical black lines) were added to the two-point segment plot. 
Additionally, a one-tailed paired t-Test was performed, and the mean, SD, and SEM were 
calculated for the average spike frequency under control and CdCl2 conditions in a total of four 
cellular recordings. This data is not represented in any figure. 
 
Results 
CaV2.2 Blockade Reduced IPSC Peak Amplitude in GABAergic IN/P-cell Synapses in the IL  
 Using the recording approach depicted in Figure 16 - top left/top middle, we found that 
IPSC peak amplitude in GABAergic IN/P-cell synapses decreases when CaV2.2 is blocked. 
Electrophysiology recordings were performed in six cells from two male and two female wild-type 
mice. Individual traces comparing IPSC peak amplitude under control, CTX, and BIC conditions 
were plotted in Figure 16 - top right. The control peak amplitude (black) is 743 pA, the CTX peak 
amplitude (red) is 523 pA, and the BIC peak amplitude (navy) is 28 pA. CaV2.2 blockade was slow 
to take effect; peak amplitude decreased over a thirty-or-so minute window before steadying 
(Figure 16 - bottom left). BIC effects were much quicker, completely eliminating IPSCs in about 
five minutes. Peak amplitude decreased in response to CTX across all recordings (Figure 16 - 
bottom right). Percentage decrease of peak amplitude from control to CTX conditions ranged from 
24% to 70%, averaging to 46% (SD = 20%, SEM = 8%). A one-tailed paired t-Test from the two-
point segment plot gives a p-value of 0.00015, meaning the CaV2.2-mediated decrease in peak 
amplitude is statistically significant. The average control peak amplitude was 331.4 pA (SD = 175 
pA, SEM = 71 pA) while the average CTX condition peak amplitude was 202 pA (SD = 161 pA, 
SEM = 66 pA).  
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Figure 16| Effects of CaV2.2 antagonism on IPSCs in GABAergic IN/P-cell synapses in the IL. IPSC 
recordings were performed in the IL of adult wild-type mice. Scale bars represent tissue width in DIC 
images and time/current values in IPSC traces. Pharmacological conditions are indicated in the color-coded 
timeline. Top left: Electrophysiology setup for IL recordings. A concentric bipolar microelectrode (yellow 
circle) is placed in the Pia/L1 to stimulate GABA release from INs while P-cells in L2/3 are patched with 
a micropipette (red circle). Top middle: Magnification of the micropipette patch of a L2/3 P-cell (red circle). 
Axons of surrounding P-cells are directed towards the medial portion of the brain slice, represented by thin 
projections at the apex of the soma. Top right: Representative traces from IPSCs in control, w-Conotoxin 
GVIA (CTX), and bicuculline (BIC) conditions. Throughout all recordings, the NMDA and AMPA/Kainate 
antagonists CPP and DNQX were present in the bath perfusion. The control (black) peak amplitude = 398 
pA, the CTX (red) peak amplitude = 222 pA, and the BIC (blue) peak amplitude is < 10 pA. Bottom left: 
Time-course plot of IPSC peak amplitude before and after bath addition of CTX (400 nM) and BIC (100 
µM). Peak amplitude begins at 400 pA but drops to under 200 pA following CTX addition. Bottom right: 
Two-point segment plot of average IPSC peak amplitude under control and CTX conditions. Each pair of 
circles represents one cellular recording (n = 6). CTX addition significantly decreases IPSC peak amplitude 
(p = 0.00015, one-tailed paired t-Test). The mean decrease was 46% (SD = 20%, SEM = 8%). Grey circles 
represent the mean IPSC peak amplitude under control (331 pA) and CTX (202 pA) conditions. Vertical 
black lines represent the SEM of each mean (71 pA and 66 pA, respectively). 
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Expression of CCK+INs in the IL  
 We present confocal images of fluorescence staining in the mPFC of an adult CCK-Dlx5/6-
tdT mouse. The slice contains mostly IL, though the bottom portion contains part of the dorsal 
peduncle and taenia tecta (Allen Mouse Brain Atlas). CCK+INs and their extensive innervation 
are observable in what morphologically appear to be L2/3 and L5 of the IL (Figure 18). tdTomato 
(red) fluorescence labels GABAergic CCK+INs and their neuronal processes while SYTO-13 
(green) fluorescence labels all cell bodies. CCK+INs are sparse in the medial region of each 
hemisphere (likely L1) and the anterior forceps of the corpus callosum (Figure 18 - left). Neuronal 
processes of CCK+INs are more apparent in the lateral aspects of the IL, with the highest 
expression located in what is likely L5. The dorsal peduncle and taenia tecta, considered by some 
as part of the ventral IL (Swanson, 2004), appear to express a considerable number of CCK+INs 
and processes. There are many non-labelled cells around which patterns characteristic of 
perisomatic inhibitory are observable (Figure 17 - left). SYTO-13 fluorescence indicates that 
medial regions of the IL (L1 and the pia) are sparse of cell bodies (Figure 17 - middle). There is a 
clustering of cell bodies in the divide between the two hemispheres, particularly where blood 
vessels are typically found. Cell bodies appear to be more tightly packed in the most medial portion 
of L2/3 but more evenly distributed in the outermost aspects of the left-hand hemisphere in Figure 
17 - middle. An overlay of tdTomato and SYTO-13 signal is located in Figure 17 - left. 
Colocalization (yellow) occurs in all GABAergic CCK+INs, which are not uniformly distributed 
throughout the slice. 
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Figure 17| GABAergic CCK Expression in the IL. Fluorescence images of a coronal brain slice 
containing the IL from an adult CCK-Dlx5/6-tdT mice. CCK+INs and their projections are tagged with 
tdTomato (red) while cell bodies are stained with SYTO-13 (green). Scale bars indicate tissue width and 
apply to all images within the figure. Left: Expression of GABAergic CCK+INs is prevalent in L2/3 and 
L5 of the IL. Superficial layers (L1, pia matter) have lower expression. Web-like patterns of GABAergic 
CCK+IN processes can be seen in L2/3 and L5. Middle: Cell bodies are sparse and disorganized in L1 and 
the pia matter. However, the deeper layers of the IL show more organized cellular patterns. Right: A two-
channel overlay of SYTO-13 and tdTomato signals shows colocalization (yellow) in the cell bodies of 
GABAergic CCK+INs. 
 
CaV2.2 Blockade did not Significantly Alter IPSC Peak Amplitude in CCK+IN/P-cell Synapses 
In Figure 18 we present data illustrating there is no statistically significant change in IPSC 
peak amplitude following CaV2.2 block in CCK+IN/P-cell synapses of the IL. The effects of CTX 
and BIC on peak amplitude were studied in eight cells from three male and three female adult 
CCK-Dlx5/6-ReaChR mice. Representative traces of IPSCs from control, CTX, and BIC 
conditions were plotted in Figure 18 - top right. The control peak amplitude (black) was 177 pA, 
the CTX peak amplitude (red) was 202 pA, and the BIC peak amplitude (navy) was 5 pA. Over a 
thirty-minute window, no statistically significant change in average peak amplitude was detectable 
(Figure 18 - left). Within ten minutes of addition to the bath perfusion, BIC eliminated IPSCs. 
Each pair of circles in the two-point segment plot represents the average peak amplitude under 
 90 
control and CTX conditions for a single cellular recording (n = 8) (Figure 18 - bottom right). 
Average peak amplitude decreased in four cells and slightly increased in another four. Decreases 
ranged from 6-49% and increases from 7-23% with a mean change of -9% (SD = 26%, SEM = 
9%). The average IPSC peak amplitude was 386 pA (SD = 282 pA, SEM = 100 pA) for control 
conditions, and 297 pA (SD = 131 pA, SE = 46 pA) for CTX conditions. A one-tailed paired t-Test 
from this plot gives a p-value of 0.122, meaning there is no statistical significance to the changes 
in average peak amplitude when CaV2.2 was blocked. 
 
Figure 18| Effects of CaV2.2 antagonism on IPSCs in CCK+IN/P-cell synapses in the IL. 
Optogenetically-evoked IPSCs were recorded from L2/3 P-cells in the IL of adult CCK-Dlx5/6-ReaChR 
mice. Left: Time-course plot of IPSC peak amplitude under control, w-Conotoxin GVIA (CTX), and 
bicuculline (BIC) conditions, indicated in the color-coded timeline. Average peak amplitude was not 
significantly altered by CTX (300 nM) addition to the bath perfusion. IPSCs were eliminated by BIC (100 
µM). Top right: IPSC traces representing peak amplitude under each pharmacological condition. Peak 
amplitude under control (black) conditions = 180 pA, CTX (red) conditions = 200 pA, and BIC (blue) 
conditions = 0 pA. Scale bars represent time and current values for IPSC traces. Bottom right: Two-point 
segment plot of average IPSC peak amplitude under control and CTX conditions. Each pair of circles 
represents one cellular recording (n = 8). The mean change was -9% (SD = 26%, SEM = 9%). Grey circles 
 91 
represent the mean IPSC peak amplitude under control (386 pA) and CTX (297 pA) conditions. Vertical 
black lines represent the SEM (100 pA and 47 pA, respectively). CTX addition to the bath perfusion did 
not statistically significantly change IPSC peak amplitude (p = 0.122, one-tailed paired t-Test).  
 
CaV2.2 Blockade did not Significantly Alter P-cell Intrinsic Firing Properties in the IL  
We present data demonstrating that CaV2.2 does not play a statistically significant role in 
the action potential spike train firing patterns, nor the spike frequency of P-cells L2/3 of the IL. A 
total of six P-cells were recorded from in this experiment, four cells from two male and two cells 
from two female wild-type mice. Firing patterns of action potential spiking under control, CTX, 
and CdCl2 conditions are located in the top-half of Figure 19. A non-adapting initial bursting 
pattern at 3.33 Hz was evoked under control conditions, a non-adapting initial bursting pattern at 
4 Hz was evoked under CTX conditions, and an adapting bursting pattern at 9 Hz was evoked 
under CdCl2 conditions. Spike frequencies remained between 3.33 Hz and 4.33 Hz under control 
and CTX conditions but increased to between 7.67 Hz and 9 Hz under CdCl2 conditions (Figure 
19 - bottom left). Each pair of circles in the two-point segment plot represents the change in firing 
frequency after CTX addition for a given cell (n = 6) (Figure 19 - bottom right). From control to 
CTX conditions, average spike frequency decreased slightly in three cells and increased slightly 
in the remaining three. Decreases ranged from 3-6% and increases from 20-39% with a mean 
change of +13% (SD = 18%, SEM = 7%). A two-tailed paired t-Test from this plot gives a p-value 
of 0.204, indicating there is no statistically significant change in P-cell spike frequency when 
CaV2.2 is blocked. CdCl2 was applied to four recordings (not shown). Increases in spike frequency 
from control to CdCl2 conditions ranged from 32-180% with a mean increase of 110% (SD = 62%, 
SEM = 31%). The average P-cell spike frequency was 4.53 Hz (SD = 1.21 Hz, SEM = .49 Hz) 
under control conditions, 5.03 Hz (SD = 1.08 Hz, SEM = .44 Hz) under CTX conditions, and 9.77 
Hz (SD = 2.82 Hz, SEM = 1.41 Hz) under CdCl2 conditions.  
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Figure 19| Effects of CaV2.2 antagonism on P-cell intrinsic firing pattern and spike frequency in the 
IL. Square-pulse currents were injected into P-cells and action potential spike trains were recorded in the 
IL of adult wild-type mice. Scale bars represents current and time values for the three firing patterns. Top 
left: Spike train evoked under control conditions. P-cell displayed a non-adapting firing pattern with initial 
bursting (3.33 Hz). Top middle: Spike train evoked under CTX conditions. P-cell continued to display a 
non-adapting firing pattern with initial bursting, but two additional spikes occurred (4 Hz). Top right: Spike 
train evoked under CdCl2 conditions. P-cell displayed a bursting firing pattern with adaptation. Activation 
threshold became more positive and the number of spikes increased dramatically (9 Hz). Bottom left: Time-
course plot of P-cell spike frequency before and after addition of CTX (300nM) and CdCl2 (100 mM) to 
the bath perfusion. Pharmacological conditions are indicated in the color-coded timeline. Spike frequency 
did not significantly change from control to CTX (300nM) conditions, but dramatically increased under 
CdCl2 (100 µM) conditions. Wash with clean aCSF partially reduced increases to spike frequency caused 
by CdCl2. Bottom right: Two-point segment plot of average spike frequency under control and CTX 
conditions. Each pair of circles represents one cellular recording (n = 6). CTX addition does not statistically 
significantly affect average spike frequency (p = 0.204, two-tailed paired t-Test). Mean spike frequency 
increase was +13% (SD = 18%, SEM = 7%) from control to CTX conditions. Grey circles represent the 
mean spike frequency under control (4.53 Hz) and CTX (5.03 Hz) conditions. Vertical black lines represent 




GABA Release from GABAergic IN/P-cell Synapses is Partially CaV2.2-dependent in the IL  
The reduction of peak amplitude in our IPSC recordings in the presence of CTX indicate 
that CaV2.2 regulates neurotransmitter release from GABAergic INs onto P-cells in L2/3 of the IL. 
The validity of this claim is supported by our procedural controls and additional observations. By 
performing all recordings in the presence of glutamatergic antagonists (CPP and DNQX), we 
ensured IPSCs contained only GABAergic components, which we additionally validated with BIC. 
Additionally, we validated that sufficient CTX concentration had been applied during each 
recording, increasing concentration by 100 nM doses incrementally up to 400 nM, even after the 
decreased in IPSC amplitude had plateaued. If CaV2.2 were either not present or had no functional 
role in GABA release, we would observe no significant changes in peak amplitude from control to 
CTX conditions. While peak amplitude decreases are reproducible, they are not uniform. There is 
likely variation in CaV2.2 expression in the presynaptic INs located in and around L1, as CTX 
conditions result in a range of decreases, from 24% to 70%. The larger decreases may represent P-
cells that are innervated by more heavily CaV2.2-dependent INs, whereas the lower decreases 
represent less CaV2.2-dependent innervation. In either case, additional CaV subtypes are likely 
involved. To determine the identity of these other CaVs, further specific CaV antagonists like SNX-
482 (CaV2.3) and ω-Agatoxin IVA (CaV2.1) could be applied during future recordings.  
CaV2.2-dependent GABA release is likely observable in multiple IL IN subtypes. 
Transgenic mouse lines labelling various IN populations with optogenetic tools could be used to 
determine the specifics subtypes involved. Previous research may indicate which IN subtypes in 
the IL are likely to express CaV2.2. A plethora of studies have described laminar organization and 
cell diversity in the mPFC and neocortex at large. It is possible these properties are conserved in 
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the IL, despite cytoarchitecture and CaV-dependent neurotransmitter release have not been 
extensively studied in this region. Cruikshank and colleagues (2012) report that INs in L1 of the 
PFC are exclusively GABAergic, but heterogeneous otherwise. Several IN subtypes located in L1 
have been shown to inhibit P-cells in L2/3. These include neurogliaform cells (Cauli, Zhou, 
Tricoire, Toussay, & Staiger, 2014) and horizontal cells (Gabbott, 2016), which form inhibitory 
synapses onto P-cell dendrites. It has been demonstrated that horizontal cells in  express N-type 
calcium channels that are involved in inhibitory feedback circuits (Liu, Hirano, Sun, Brecha, & 
Barnes, 2013). These findings were from horizontal cells which innervate photoreceptors, thus 
further studies would need to be done to confirm horizontal cells in the IL also express these 
properties. More directly associated with CaV2.2 expression in the mPFC, CCK+INs are addressed 
in their respective section of this discussion.  
Previous research may also indicate which IN subtype in the IL are not likely to express 
CaV2.2. GABA release from neurogliaform cells in L1 (Allene et al., 2015) may be facilitated by 
L-type CaVs, as this has been shown for their hippocampal analogues (Li et al., 2014). Martinotti 
cells, whose soma are distributed in the IL layers which contain P-cells, have long GABAergic 
projections which synapse onto P-cell dendrites in L1 (Allene et al., 2015; Cauli et al., 2014). 
Martinotti cells have been shown to express L-type CaVs (Wang et al., 2004). GABA release from 
PV+BCs, located in the same layers as Martinotti cells and P-cells, is likely facilitated by P/Q-
type CaVs (Bartos & Elgueta, 2012). As these three IN subtypes have been shown to express non-
N-type channels in other brain regions, they may still release GABA onto L2/3 P-cells after CaV2.2 
block. Accordingly, it is possible the CTX condition IPSCs we recorded were due to GABA release 
from PV+BCs, Martinotti cells, and neurogliaform cells. 
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Localization of CCK+INs in the IL 
 Fluorescence experiments in our triple transgenic mouse line (CCK-Dlx5/6-tdT) reveal 
CCK+IN expression throughout the mPFC, with variability across layers (Figure 18 - left). 
Perisomatic inhibitory cells, CCK+BCs and PV+BCs, have been described in the superficial and 
deep layers (L2/3-L6) of the mouse IL, PL, and dorsal peduncular area (DP) (Whissell et al., 2015). 
CCK+BCs are reported to be the most numerous type of IN in the mPFC, and are significantly 
more prevalent than PV+BCs in the IL and DP (Whissell et al., 2015). Our fluorescence images 
appear to display similar patterns of pervasive CCK+IN expression in L2/3 and L5, as most cells 
appear morphologically to be innervated by the neuronal processes of CCK+INs. Innervations by 
CCK+INs in the mPFC are vital for regulating excitatory output; dysfunction in this system has 
been linked to the pathogenesis of anxiety disorders (Bachus, Hyde, Herman, Egan, & Kleinman, 
1997). Interestingly, we observe the presence of CCK+INs in what laminarly appears to be L1. 
This expression pattern has not been specifically reported in the mouse IL before. While CCK+INs 
have been shown to be present in L1 of the developing mouse neocortex, CCK mRNA was the 
least abundant compared to other neuropeptide markers like calbindin and neuropeptide-Y (J Ma 
et al., 2014). Via SYTO-13 labelling, the number of cells located in L1 is relatively low compared 
to deeper layers. It has been reported that cells in L1 of the PFC are exclusively GABAergic INs 
(Cruikshank et al., 2012). Only a fraction express GABAergic CCK in our composite image 
(Figure 18 - right), which may be reflective of the low CCK mRNA content described by J Ma 
and colleagues (2014). 
L1 CCK+INs likely possess different intrinsic properties and target different cell 
populations compared to CCK+INs in L2/3 and L5. As P-cell somas are located in L2/3 and L5 
while their dendrites are located in L1 (Riga et al., 2014), L1 CCK+INs may be involved in 
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dendritic inhibition rather than perisomatic inhibition. Accordingly, the synaptic properties of L1 
CCK+INs may be more similar to neurogliaform, horizontal, and/or Martinotti cells than 
CCK+BCs. It appears the web-like GABAergic CCK+ expression patterns of the deep IL layers 
are also present in L1, though to a much lesser extent. This could be due to there being a lower 
number CCK+INs present in L1, but the inhibition patterns of these cells could also be different. 
Morphological studies like biocytin stainings could be used to determine the neuroanatomical 
differences between L1 and L2/3 and L5 CCK+INs. The extensive GABAergic CCK+IN 
expression we observed in confocal images from our CCK-Dlx5/6-tdT mouse model are a 
promising sign for their potential extensive regulatory role on P-cell output in the circuits related 
to fear extinction.  
 
CaV2.2 Block does not Significantly Affect GABA release in CCK+IN/P-cell Synapses in the IL  
 Note: While our optogenetic mouse model (CCK-Dlx5/6-ReaChR) labels all GABAergic 
CCK+INs, optogenetic stimulation likely evokes GABA release primarily from CCK+BCs in L2/3. 
CCK+BCs are involved in perisomatic inhibition networks with local P-cells (Eggan et al., 2010; 
Freund & Katona, 2007) and are more numerous than non-basket cell CCK+INs (Bachus et al., 
1997; J Ma et al., 2014). However, contribution of non-basket cell CCK+INs (possibly in L1) 
cannot be ruled out, so results must be applied to the entire population of CCK+INs in the IL.  
Contrary to our findings regarding CCK+INs in the BLA (CHAPTER 1), CCK+INs in the 
IL did not display CaV2.2-dependent neurotransmitter release properties. Accordingly, CCK+INs 
may differ in their CaV2.2 expression/function across brain regions. While GABA release from 
hippocampal CCK+INs is entirely CaV2.2-dependent (Szabo et al., 2014), it may be partially 
CaV2.2-dependent in the BLA (CHAPTER 1), and not statistically significantly CaV2.2-dependent 
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in the IL. However, the lack of CaV2.2-dependent GABA release may not apply to every CCK+IN 
in the IL. In two of our recordings, we observed moderate IPSC peak amplitude decreases (47% 
and 49%) following CaV2.2 blockade. It could be that in these two cells, selected randomly from 
L2/3 of the IL, GABA release was partially CaV2.2-dependent. However, in the cumulative 
population of CCK+INs we performed pharmacological recordings in, we did not observe 
statistically significant CaV2.2-dependent GABA release. 
In addition to differential CaV2.2 expression, variations in CaV2.2-dependent GABA 
release could be the result of differential CaV2.2 modulation across CCK+IN subtypes. In several 
recordings, we observed an initial decrease in IPSC peak amplitude after CTX addition similar to 
the time-course plots from Figures 13 and 16. However, this initial decrease was temporary; after 
approximately twenty minutes IPSC peak amplitudes began to return to control condition values. 
It is possible a compensatory mechanism was responsible for this observation. The presynaptic 
CCK+IN terminal may have compensated for the CaV2.2 blockade, or the P-cell membrane may 
have compensated for the decreased GABA binding. Inchauspe and colleagues (2004) report 
functional compensation between CaV subtypes: N-type channels compensated for the absence of 
P/Q-type channels and evoked synaptic currents at the Calyx of Held. Given P/Q-type channels 
contribute to the maintenance of neurotransmission by providing additional faciliatory drive 
(Inchauspe, 2004), it is theoretically possible they could compensate for N-type calcium channel 
block if co-expressed in presynaptic terminals. If present in CCK+IN terminals, this compensatory 
mechanism could lead to much smaller decreases in IPSC peak amplitude following CaV2.2 block 
when compared to control conditions. In addition to functional compensation by other CaV 
subtypes, CTX may modulate CaV2.2 differently in the CCK+INs of the IL compared to those in 
the HPC or BLA. While CTX is generally considered an irreversible blocker, N-type calcium 
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current recovery was observable under certain conditions, like in the absence of divalent cations 
(Liang & Elmslie, 2002). It is unlikely we would observe this in the IL and not the BLA however, 
as our brain slice preparation and internal and external solutions remained consistent.  
Comparisons between our two-point segment plots in Figures 16 and 18 allow for more 
specific conclusions to be made regarding CaV2.2-dependent neurotransmission. The statistically 
significant decrease (mean = 46%) in neurotransmitter release from GABAergic INs following 
CaV2.2 block is not facilitated by CCK+INs. We observed transmitter release from CCK+INs did 
not significantly change (average 9% decrease) following CaV2.2 block. Speculation as to what 
presynaptic GABA release is blocked by CTX includes horizontal cells and non-compensatory 
CCK+INs. Overall, there are many possible reasons as to why we did not see statistically 
significant changes to IPSC peak amplitude with CTX in CCK+IN/P-cell synapses. Regardless of 
the underlying mechanism(s), our observations were reproducible. A likely and concise conclusion 
is that in the IL, CaV2.2 does not play a critical role in GABA release from presynaptic CCK+INs. 
 
Pyramidal Cell Spiking is not Significantly Modulated by CaV2.2 in the IL  
 Under control, CTX, and CdCl2 conditions, we observed ‘initial burst’ patterns from L2/3 
P-cells in the IL. Initial bursting occurs when a neuron responds with a significantly greater spike 
frequency upon initial current injection, before slowing to a steady-state pattern. Initial bursting is 
caused by a series of ‘direct resets’, wherein the cell almost immediately fires from the membrane 
potential at which its previous spike ended (Gerstner, Kistler, Naud, & Paninski, 2014). We 
observed two direct resets under control and CTX conditions and four under CdCl2. Steady-state 
patterns are the result of ‘detour resets,’ which occur when a neuron makes a ‘detour’ into the 
region of negative membrane potential (hyperpolarizes) at the beginning of the spike interval 
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(Schwalger & Lindner, 2013). Detour resets comprise the entirety of the steady-state phase, which 
can be categorized by the patterns produced by inter-spike intervals (ISIs). Under control and CTX 
conditions, we observe ‘regular-spiking’ firing patterns (equal ISIs), which are also referred to as 
normal, tonic, non-adapting, or non-accommodating. Similar patterns have been previously 
reported from P-cells in the IL (Ferreira et al., 2015), the mPFC (Van Aerde & Feldmeyer, 2015), 
and the BLA (Rainnie et al., 1993). Under CdCl2 conditions, we observed what appear to be 
gradually increasing ISIs, indicative of an adapting or accommodating firing pattern (Gerstner et 
al., 2014). Though there are multiple ways to classify firing patterns, the intrinsic cellular 
properties producing these patterns are consistent regardless of naming scheme. 
There was a distinct change in firing pattern when CdCl2 was applied to P-cells in L2/3 of 
the IL. The ISI decreased dramatically from CTX and control patterns, and the direct reset phase 
lasted far longer. CdCl2 acts as a calcium channel antagonist, blocking all CaVs (Gadbut, Cash, 
Noble, Radice, & Weyhenmeyer, 1991). Thus, the changes we observe from CTX to CdCl2 
conditions are due to a combination of P/Q-, L-, T-, and R-type blockade. CaVs allow for prolonged 
calcium conductance during each spike, which produces long-duration action potentials in P-cells 
when compared to faster spiking interneurons (Rainnie et al., 1993). When CaVs are blocked, it is 
likely that calcium entry is no longer prolonged, and thus action potential duration shortens. Along 
similar lines, calcium channel modulation has been shown to promote burst firing patterns from 
regular firing neurons (Friedman & Gutnick, 1989; S. Rudolph, Hull, & Regehr, 2015). These 
concepts are reflected in our experimental design; as we blocked CaVs, we saw greater firing 
frequency (< 1 Hz with CTX, > 4 Hz with CdCl2) and an upregulation of bursting. Overall, we can 
make specific conclusions only for the control and CaV2.2 blockade conditions, as CdCl2 is not a 
specific antagonist like CTX (Gadbut et al., 1991). The lack of statistically significant changes to 
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firing properties we observed following CTX addition indicate that CaV2.2 is not an integral 
somatic modifier of P-cell intrinsic firing properties. CaV2.2 in the presynaptic terminal of INs has 
a far more important regulatory role over P-cell activity, therefore is likely the more appropriate 
pharmacological target for regulating anxiety-related neuronal output.  
 
Additional Considerations for Future Research 
The infralimbic cortex, as well as the larger medial prefrontal cortex, present many 
opportunities for novel circuit-level functional studies of CaVs. Having observed a robust decrease 
in IPSC peak amplitude in GABAergic IN/P-cell synapses following CaV2.2 block, further 
investigations of presynaptic inhibition at the level of P-cell dendrites are warranted. Given the 
average IPSC peak amplitude decrease was 46%, there are likely other CaV subtypes which 
facilitate the remaining release of GABA. Emulating our previous recordings, the L-type blocker 
Nimodipine could be introduced to the bath following CaV2.2 block. Martinotti and neurogliaform 
cells express L-type channels (Li et al., 2014; Y. Wang et al., 2004), so we predict IPSC peak 
amplitude would further decrease. If IPSCs are not fully eliminated by N- and L-type blockade, 
ω-Agatoxin IVA could be added to the bath perfusion to block P/Q-type channels, which are 
expressed in PV+BCs (Bartos & Elgueta, 2012; Freund & Katona, 2007; Zamponi & Currie, 2013). 
By altering the layer of the IL in which we recorded and/or stimulated, many additional circuits 
could be studied. For example, simulating L1 and recording from L5 would allow for comparisons 
of dendritic inhibition strength in deep L5 P-cells and superficial L2/3 P-cells. It may be that deeper 
IL-BLA connections are not as robustly regulated by CaV2.2, in which case other receptors may 
be better targets for reducing inhibition of fear extinction.  
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 As the PL and IL have been shown to influence distinct fear and anxiety-related processes 
(Sierra-Mercado et al., 2011), it stands to reason that there could be circuit-level differences 
between the two mPFC areas. It has been demonstrated that L5 neurons differ morphologically 
based on projection target; the PL and IL differ greatly in this regard (Ferreira et al., 2015). 
Irrespective of established cellular differences, functional studies must be run to confirm if 
morphologically distinctive cells express unique CaVs and process presynaptic inhibition 
differently. In a future experiment, we could replicate our IL recordings to test if CaV2.2 plays a 
significant role in neurotransmitter release in the PL, focusing on cell populations with known 
synaptic and/or intrinsic differences. Our goal would be to describe if and how CaV2.2 
differentially regulates two distinct mPFC regions involved in fear expression and extinction. 
Investigations into the role of eCB-dependent and independent CB1 modulation of CaV2.2 
could be performed on dendritic and perisomatic inhibitory networks in L2/3 of the IL. CB1 
receptor signaling within the mPFC has been shown to potentiate emotional associative learning 
through inputs from the BLA (Laviolette & Grace, 2006). However, Laviolette and Grace (2006) 
performed extracellular recordings so cell-specific effects were not observable; an entry point from 
which we could make novel contributions regarding CaVs. Additionally, CB1 is known to be 
expressed in the CCK+INs in the PFC which also express CaV2.2 (Marsicano & Lutz, 1999). 




OVERALL CONCLUSIONS  
By investigating the regulation of excitatory output from the BLA, we are interested in 
determining new cell-specific targets to mitigate anxiety. Before this is possible, the basic cellular 
and molecular mechanisms underlying the relationship between INs and P-cells must be 
understood. CaV2.2 has been shown to modulate neurotransmitter release from CCK+INs in the 
hippocampus, but its role in the BLA had not been functionally described. With our novel triple 
transgenic mouse model, we used optogenetics tools to isolate CCK+IN/P-cell synapses for 
functional studies. We found that GABA release from CCK+INs was modulated by CaV2.2 in the 
BLA as hypothesized. But, this modulation was only partial. The average peak amplitude of 
inhibitory postsynaptic currents was roughly halved following CaV2.2 blockade, whereas studies 
of CCK+INs in the HPC would suggest total elimination of current. Our data show that while cell 
circuitry may be conserved, CaV2.2 differentially regulates neurotransmitter release from 
CCK+INs in the BLA and HPC. We present a challenge to the theory that CaV2.2 is the only CaV 
involved in regulating neurotransmitter release from CCK+INs. As CaVs are vital in regulating 
neuronal activity, extensive and comprehensive investigations are warranted to uncover more 
details as to their role in GABA release from INs in the BLA.  
CCK+IN terminals in the BLA almost uniformly express type-1 cannabinoid receptor. 
Upon activation by cannabinoids, these receptors are believed to suppress inhibitory 
neurotransmitter release and disinhibit P-cells, thus profoundly impacting amygdalar output. The 
functional studies required to confirm these predictions were not yet published upon the start of 
our research. Beginning with immunofluorescence experiments, we found comparable 
colocalization of CB1 and GABAergic CCK expression in the BLA and HPC. Our initial 
electrophysiology data suggests that CB1 is involved in both phasic and tonic inhibition of 
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neurotransmitter release from CCK+IN in the BLA. CB1-agonism lead to a decrease in IPSC peak 
amplitude, as CB1 inhibits calcium entry though CaVs. Contrarily, CB1-antagonism lead to an 
increase in IPSC peak amplitude, as tonic levels of CB1-mediated inhibition of CaVs were 
eliminated. A paper published by Rovira-Esteban and colleagues (2017) comprehensively 
described the modulation of CCK+IN/P-cell synapses in the BLA by CB1, thus we discontinued 
further recordings. Our hypothesis and preliminary data suggest reproducibility of the findings 
presented by Rovira-Esteban and colleagues (2017). Ultimately, CB1-containing CCK+INs may 
control anxiety at the level of the amygdala and are potential targets for regulating anxiety-related 
neuronal output.   
Anxiety disorders are often associated with the inability to extinguish fearful or traumatic 
memories, a process which in mice is thought to be facilitated by the infralimbic cortex and its 
connections to the BLA. The IL is a promising target for anxiety research, as CaV physiology is 
relatively understudied despite proposed functional significance. We found that CaV2.2 was not an 
integral modulator of P-cell intrinsic firing properties, as CTX had negligible effects on firing 
pattern and spike frequency. CaV2.2 displayed a far more significant regulatory role over P-cell 
activity in presynaptic INs, which are likely a more appropriate pharmacological target for 
regulated neuronal output involved in the extinction of conditioned fear. Our initial 
electrophysiology experiments suggest that neurotransmitter release from GABAergic inputs in 
L1 of the IL onto P-cells in L2/3 is partially CaV2.2-dependent, similar to our observations in the 
BLA. However, the approximate halving of IPSC peak amplitude is not facilitated by CCK+INs, 
as our data show neurotransmitter release from these INs is not significantly modulated by CaV2.2.   
Overall, our experiments lay groundwork for future functional studies on the role of CaVs 
in anxiety-related circuits. We demonstrate that although CCK+IN/P-cell synapses are found in 
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the HPC, BLA, and mPFC, they are differentially regulated by CaV2.2. Therefore, novel 
pharmacological treatments for anxiety that target CaV2.2 should consider region-specific effects. 
CaV2.2 block likely has therapeutic value in certain neuronal circuits and brain regions, but no 
value or even detrimental effects on others. For example, anxiety-related brain activity may be 
suppressed in the HPC while simultaneously upregulated in the BLA. Differential effects may be 
seen within the mPFC, as upregulation of P-cell activity could facilitate fear-extinction in the IL, 
but perpetuate fear expression in the PL. Accordingly, more information must be revealed about 
the role of CaV2.2 in anxiety-related neuronal circuits to ensure the safety and efficacy of 
developing treatments for anxiety disorders. 
As it pertains to the data presented within these chapters, future research should 
comprehensively describe the role of each CaV subtype involved in CCK+IN/P-cell synapses in 
the BLA and IL. By blocking CaV subtypes in sequential order, we could fully eliminate IPSCs 
and determine which are responsible for the remaining IPSC peak amplitude observed in 
CHAPTER 1 and CHAPTER 3. Pharmacological agents would need to include Nimodipine (L-
type blocker), ω-Agatoxin IVA (P/Q-type blocker), and SNX 482 (R-type blocker). Given the 
discrepancies we observed in CCK+INs across brain regions, it is reasonable to propose 
investigations into CaVs in CCK+INs in additional limbic structures like the periaqueductal grey, 
anterior cingulate, and central amygdala. On a larger scale, our mouse models serve as a tool for 
potential studies on the anatomical, intrinsic, synaptic, and behavioral properties of CCK+INs 
throughout the brain.  
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